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CHAPTER 1: REVIEW OF LITERATURE
1.1 Introduction
1.1.1 Stem Cells
Stem cells have amazing potentials to develop into many different cell types during growth,
especially early in life. Most importantly, many of these stem cells serve as internal repair systems,
dividing without limit to replenish other cells and tissues (1). When stem cells divide, they can
become another type of cell with a more specialized function, such as a brain cell or they can
remain a stem cell. Stem cells have three notable characteristics: they are unspecialized, can selfrenew, and under physiological or experimental conditions, they can be induced to become organspecific cells (1). Scientists used to only have two kinds of stem cells to work with: embryonic
stem cells (ESC) and non-embryonic adult stem cells.
In mammalian development (Figure 1-1), only the zygote and early blastomeres are
totipotent and can generate the whole organism (2). ESCs are derived from the inner cell mass
(ICM) of mammalian blastocysts which have unlimited ability to self-renew and are pluripotent.
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Figure 1-1: Diagram of Genetic and Epigenetic Regulation of Pluripotency during Mouse
Development. The totipotent zygote contains maternally inherited epigenetic modifiers and
transcription factors, including Oct4, Sox2, and Exh2. These together with the embryonic
transcripts regulate development to the blastocyst stage, where the pluripotent cells are established
in the inner cell mass (ICM). Deletion of Oct4 and Nanog comprises the development of the ICM
(8-10). In the post-implantation embryo, pluripotent epiblast cells are controlled by diverse
repressive mechanisms during their differentiation into somatic and germ cell lineages (the latter
of which undergo specification following repression of the somatic program). The early germ cells
exhibit epigenetic and transcriptional states that are associated with pluripotency, and the ensuing
epigenetic reprogramming within this lineage re-generates totipotency. The figure depicts the main
epigenetic changes occurring during critical stages of development (2).
The term pluripotent means that cells can differentiate into any cell of three germ layers:
ectoderm, endoderm, and mesoderm (2-8). Pluripotent cells may differentiate to become
multipotent progenitor cells, such as neural stem cells (NSCs), which then may differentiate into
cell types of the neurogenic lineage only (1). Moreover, unipotent cells, such as skin cells, can
only differentiate into only one cell type (3). A summary of the different types of potency can be
found in Table 1-1.
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Table 1-1: Definitions of the Different types of Potency (3).
Potency
Sum of developmental options accessible to cell
Totipotent
Ability to form all lineages of organism; in mammals only the
zygote and the first cleavage blastomeres are totipotent.
Pluripotent
Ability to form all lineages of body. Example: embryonic stem
cells
Multipotent
Ability of adult stem cells to form multiple cell types of one
lineage. Example: hematopoietic stem cells
Unipotent
Cells form one cell type. Example: spermatogonia stem cells (can
only generate sperm)
Reprogramming
Increase in potency, dedifferentiation. Can be induced by nuclear
transfer, cell fusion, genetic manipulation
Transdifferentiation,
Notion that somatic stem cells have broadened potency and can
plasticity
generate cells of other lineages, a concept that is controversial in
mammals.
In 1981, scientists discovered a way to derive ESCs from early mouse embryos, which led
to the 1998 discovery of a technique to derive stem cells from human embryos to grow in the lab
and are referred to as human embryonic stem cells (hESCs) (Figure 1-2) (9, 10). The first cultured
hESC line was established and revealed the promise for stem cells in future clinical therapies.
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Figure 1-2: How Embryonic Stem Cells are Derived. Adopted from the National Institute of
Health (NIH) Web site www.stemcells.nih.gov (7).
1.1.2 Neurodegenerative Diseases and Stem Cell Potential
ESCs have been used as tools for studying developmental biology (11). More recently,
ESCs have become of great interest in generating transgenic animals, drug screening, and potential
cell therapies for regenerative medicine to address degenerative diseases (11). It has been realized
that pluripotent cells possess the distinct potential to be utilized in the treatment of
neurodegenerative diseases through the differentiation to neurogenic cells for transplantation
(Figure 1-3).
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Figure 1-3: Characteristics of Embryonic Stem Cells. Adopted from the National Institute of
Health (NIH) Web site www.stemcells.nih.gov (7).
Neurodegeneration is a complex process that causes neuronal death in the central nervous
system (CNS) and the peripheral nervous system (PNS), resulting in damage or dysfunction (12).
“This damage further causes oxidative stress, axonal transport deficits, protein oligomerization,
aggregation,

calcium

deregulation,

mitochondrial

dysfunction,

abnormal

neuron–glial

interactions, neuroinflammation, DNA damage, and aberrant RNA processing” (12). There are
hundreds of different neurodegenerative diseases, however, the most attention is paid to
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Parkinson’s disease, Huntington’s disease, schizophrenia, amyotrophic lateral sclerosis,
Alzheimer’s disease, and spinal muscular atrophy (5, 13). Many of the less broadcasted
neurodegenerative disorders, though not less devastating, have been technically ignored (13).
Fascinatingly, increasing age is the most consistent risk factor for developing a
neurodegenerative disorder (11). Today, the growth rate of the population aged 65 and over has
very much surpassed than that of the whole population combined (14, 15). Thus, many anticipate
that, over the next generations, the proportion of elderly citizens will double. As expected, the
proportion of persons suffering from neurodegenerative disorders will also be doubled, triggering
an increased emotional, physical, and especially financial burden on society (15).
The ability to isolate human embryonic stem cells (hESCs) is key for research and clinical
applications. However, there are ethical concerns that come behind the use of human embryos for
studies and cell therapies (5). One must also consider the complications of potential immune
responses that some patients undergo during allogenic therapies (5). For these reasons, the ability
to generate patient-specific somatic cell-derived induced pluripotent stem cells is of great interest
to medical and scientific communities (5). In 2006, researchers made a discovery by classifying
conditions that would allow some specialized adult cells to be genetically reprogrammed to assume
an embryonic stem cell-like state called induced pluripotent stem cells (iPSCs) (5). From then on,
scientists have developed techniques towards discovering more effective methods to reprogram
somatic cells to other highly valuable stem cells.
1.1.3 Network and Molecular Mechanisms of Pluripotency
Mechanisms of pluripotency are still not entirely understood. However, scientists have
clarified the master regulators of the pluripotency network; Sox2, Oct4, and Nanog (SON) proteins
(16). Oct4 (octamer-binding protein) is a transcription factor and a key regulator of stem cell
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pluripotency (5 & 17). It has also been discovered that the expression of Oct4 is limited to the
inner cell mass (ICM) in a developing embryo and is maintained in adult germ cells but
downregulated in differentiated somatic cells (16 & 17). When scientists knockout Oct4 in
embryos, they die after the blastocyst stage and fail to develop an ICM indicating its essential role
in normal mammalian embryonic development (18). Moreover, reduced expression levels of Oct4
in embryos leads to the spontaneous differentiation into the trophoblast lineages (18). This
indicates the identity of Oct4 as part of a pluripotent maintenance mechanism (18). Furthermore,
an increase in the expression levels of Oct4 in embryos, induces differentiation into primitive
endoderm and mesoderm stages (19-21). Therefore, the Oct4 gene expression level precisely
regulates the pluripotent state of ESCs.
Sox2, (SRY-related HMG-box) is also a transcription factor that is highly expressed in the
pluripotent lineage of the early embryos (22). Like Oct4, Sox2 plays an important role in
maintaining pluripotency and its expression is confined to the ICM, epiblast of early embryos, and
germ cells (22). In contrast to Oct4, however, Sox2 is also expressed in the extraembryonic
ectoderm and in precursor cells in the early and adult nervous system (22 & 23). Moreover, Sox2
knockout embryos fail to develop epiblast and die at the implantation stage (24). Additionally, a
reduced level of Sox2 in ESCs is associated with a loss of pluripotency and a tendency to
differentiate (25 & 26). Furthermore, it’s been reported that Sox2 and Oct4 work synergistically
to control the expression of specific ESC genes by forming protein-heterodimers (26-28) and
regulate expression of Oct4 itself (25). Moreover, Sox2 is a key component of the transcriptional
regulatory networks, which maintains the totipotency of the cells during embryonic
preimplantation period, the pluripotency of embryonic stem cells, and the multipotency of neural
stem cells (NSCs) (30).
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Nanog (homeobox protein) is also a transcription factor that was discovered based on its
ability to maintain ESC self-renewal in the absence of leukemia inhibitor factor (LIF). LIF is used
to maintain cultured mouse ESCs in an undifferentiated state (12 & 31). For instance, Nanog-null
mouse embryos fail to maintain a pluripotent epiblast, while disruption of Nanog in vitro results
in an increased tendency of ESCs to spontaneously differentiate (31 & 32). Nanog has been shown
to act as a strong activator of Oct4 (33). “When the ESCs experience a drop in Nanog levels, they
cause upregulation of transcription factors that are involved with trophectoderm differentiation,
indicating that Nanog helps sustain pluripotency by repressing these differentiation factors” (32).
Other reports suggest that Nanog is upregulated in embryonic based tumors (10). However, Nanog
is not strongly correlated with cancers in human adults (20, 34). Sox2, Oct4, and Nanog, serving
as master regulators, make up the pluripotency autoregulatory circuit, which maintains the
pluripotency of ESCs (30) (Figure 1-4).
The roles that SON transcription factors play during early development suggest that these
master regulators are critical to a transcriptional regulatory mechanism that controls ESC identity
(6). To find genes that are occupied by SON, scientists have utilized genome-wide location
analysis and chromatin immunoprecipitation (ChIP) in hESCs (6). They found significant insights
on the ability of these transcription factors to regulate the pluripotency of cells (10, 36). Firstly,
SON proteins bind to their own promoters and to each other’s promoters to form an autoregulatory
circuit (Figure 1-4) (6). Secondly, as regulators, SON mostly occupy their target genes to maintain
pluripotency and repress differentiation. The autoregulatory circuit of the SON regulator system
ensures that gene expressions are maintained in ESCs so that pluripotency can be maintained.
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Figure 1-4: Schematic Diagram of Autoregulatory Circuit. SON form an interconnected
autoregulatory circuit, by targeting both their own promoters and those of each other. In this way,
the three key transcription factors can maintain their own expression, thereby contributing to the
maintenance of pluripotency. Proteins are depicted as circles, gene promoters as rectangles. (6)
SON factors have also been identified to target hundreds of other genes in ESCs (6) (Figure
1-5), mainly including two types of ESC genes. The first type of gene family contains pluripotency
genes, where the SON factors bind to the promoter regions of these genes to activate their gene
expression. The second sets of genes include differentiation genes that remain silent until cell
differentiation (10). During the embryonic state, the SON factors bind to the repressors of these
second set of genes set to silence their gene expression. The activation of gene expression of this
second set of genes causes differentiation and the SON factors bind to the promoter regions of
these ‘silent genes’ to activate their gene expression for induction of differentiation. Therefore, the
SON master regulator factors regulate a cell’s fate through the interactions with the promoters and
repressors of specific genes (10). It has also been discovered that the SON master regulator
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autoregulatory circuit responses to external stimuli, which implies that pluripotency could be
maintained through developmental stimuli (10).

Figure 1-5: Diagram of SON Transcriptional Network. The SON trio contribute to ESC
pluripotency by repressing genes linked to lineage commitment and activating genes involved in
pluripotency. Active genes include, besides Oct4, Sox2, and Nanog themselves, ESC-specific
transcription factors, components of ESC signaling cascades, and epigenetic enzymes. In contrast,
repressed genes comprise regulators of differentiation into the three germ layers and
extraembryonic development. Proteins are depicted as circles and gene promoters as rectangles
(6).
SON co-occupy different genes, meaning that they work together to maintain pluripotency
(3-6). STAT3, SKIL, ZIC3, and REST are a few of the transcription factors that are transcribed
for pluripotency. Chromatin-modifying enzymes such as SET or signal transduction components
such as DKK of the Wnt pathway or Lefty2 of the TGF-β pathway are other genes for pluripotency
(10, 36). SON are involved in epigenetic complexes that further represses the transcription of
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‘silent’ differentiation genes that translate to proteins of the Polycomb group, chromatin
remodeling complexes, and histone deacetylase complex (37). Moreover, expressed factors are all
known to maintain the pluripotency of ESCs and their self-renewal, while the silent genes, such as
Pax6, are involved with differentiation of the cells to specific lineages (10, 36). The expression of
silent genes that translate to developmental transcription factors like Pax6, are associated with the
differentiation to neurogenic lineage commitment. These factors have established the formation of
models to uncover the downstream of cellular differentiation.
1.1.4 Most Effective Stem Cells for Neurodegenerative Disorders
Over the past 14 years, cell reprogramming techniques have been widely applied to
generate induced pluripotent stem cells (iPSCs) (5, 38, 39). Many patient-specific iPSC-lines have
been established for specific diseases such as Parkinson’s disease (40, 41, 46), Huntington’s
disease (40) schizophrenia (42), amyotrophic lateral sclerosis (43), Alzheimer’s disease (44), and
spinal muscular atrophy (45). However, for therapeutic application, iPSCs need to be efficiently
differentiated into the desired specific lineage cell type (Figure 1-6).
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Figure 1-6: Generation and use of iPSC Modelling in Parkinson’s Disease (PD). Somatic cells
from a diseased patient are isolated and then reprogrammed to a pluripotent state (iPSCs). iPSCs
can be maintained in culture or induced to differentiate along tissue- and cell-type specific
pathways. Differentiated cells can be used to elucidate disease mechanism pathways, as well as
for the development of novel therapies (46).
Moreover, the cells derived from iPSC and undifferentiated iPSCs exhibit potential
tumorigenic risks (29, 47, 48, 49) and limit their direct use in cell transplantation applications. This
makes PSC differentiation mechanisms highly attractive. With that said, Pluripotent stem cells
such as ESCs and iPSCs can form teratomas in vivo, whereas multipotent, lineage-restricted stem
cells such as induced neural stem cells (iNSCs) and hematopoietic stem cells do not (29, 47, 48,
49). “Reprogramming somatic cells into less potent, lineage-restricted cells will sidestep the
difficulty of differentiating iPSCs, thus lowering the risk of teratoma formation, while
complementing iPSC technology” (29).
Transcription factors have been previously used to induce a change in cell fate from one
type of cell to another (5, 29, 38, 39, 50, 51, 54, 55). Induced multipotent adult stem cells such as
iNSCs, induced cardiac progenitor cells, induced functional neuronal cells, and cardiomyocytes
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have been generated from somatic cells. In particular, the generation of induced neuronal cells
(iNCs) from somatic cells provided a new avenue for research in transplantation therapies for
neurodegenerative disorders. Although iNCs have typical neuronal cell properties such as
exhibiting proper electrical function in culture and can be generated with high efficiency (5%20%), clinical applications must consider the inability of iNCs to self-renew in culture because
they are terminally differentiated (29). Terminally differentiated means that there is a restriction
in cell fate to only a few neuronal sub-types. Moreover, current reprogramming methods generate
a mixture of neuronal cells and other unknown types of cells, limiting the use of iNCs for
transplantation therapy (Figure 1-7). In figure 1-7 iNCs are referred to as neural progenitors.
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Figure 1-7: Potential Stem Cells with Neural Capability. An illustration proposing the classes of
mammalian stem cells that can give rise to neurons presented as a hierarchy beginning with the
most primitive and multipotent stem cell and progressing to the most restricted. The restrictions of
fate at each step and examples of sites in the body where they can be obtained are also presented.
As our understanding of the true potential and nature of stem cells is still unfolding, modifications
will be added. For example, the small arrows pointing up suggest the potential, although not well
documented, dedifferentiation of the more restricted cell below (52).
Although many studies have shown the generation of iNCs from mouse and human somatic
fibroblast cells (53, 54, 55, 56, 57), these cells are terminally differentiated which results in a
restriction in cell fate to only a few neuronal subtypes. In all, the generation of patient-derived
multipotent iNSCs is more advantageous than the generation unipotent (iNCs) because multipotent
cells express greater self-renewing capacity and passaging ability, along with limited potential
(Figure 1-7).
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1.1.5 Neural Stem Cells and Neurogenesis
NSCs were first identified within the CNS in the year 1992 (58). Overall, the ability to
efficiently reprogram somatic cells into self-renewable, multipotent, nontumorigenic, and neurallinage restricted iNSCs, may have major implications in regenerative medicine for
neurodegenerative diseases. “The most common brain cells are neurons and glial cells” (59). Glial
cells are the astrocytes and oligodendrocytes of the CNS. NSCs are very powerful model systems
for neurodegenerative disease transplantation therapies because they are only able to make three
types of cells; astrocytes, oligodendrocytes, and neurons (Figure 1-8). “Furthermore, NSCs
secrete therapeutic molecules like soluble factors, including neurotrophic factors, growth factors,
and cytokines, that protect existing neural cells against damage in situ” (60). Neurotrophic factors
regularly released from NSCs improve a lesion’s microenvironment, therefore generating suitable
conditions for damaged neural tissue repair (60, 61, 62, 63).
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Figure 1-8: NSC Properties for Therapeutics. NSCs secrete soluble factors, including
neurotrophic factors, growth factors, and cytokines, thus protecting existing neural cells against
damage in situ. Furthermore, they differentiate into neurons, astrocytes, and oligodendrocytes via
committed progenitor stages to replace lost neural cells. Either neural protection or cell
replacement may aid in neurological functional recovery after acute or chronic injury via neural
regeneration (60).
Multipotent adult stem cells, which are adult stem cells such as hematopoietic stem cells,
mesenchymal stem cells, and NSCs, exist throughout the adult human body and play important
roles in tissue maintenance and repair. Until now, the reason for the age-associated decline in selfrenewing capability and differentiation potential of multipotent stem cells in tissues is unclear.
Like pluripotent stem cells, multipotent stem cells can self-renew and proliferate. However,
multipotent stem cells can only develop into multiple specialized cell types for specific tissue or
organ versus pluripotent stem cells that can generate any cell in all three germ layers. The
discovery of stem cells that can directly generate neural tissue has raised new possibilities for
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repairing the CNS. NSCs, with self-renewal ability that are multipotent and able to generate
multiple neural lineages, including glia, and neurons, are derived from regions throughout the adult
CNS (64).
The major function of neurons is the transmit information mostly through biochemical
mechanisms. The typical neuron consists of a cell body, dendrites specialized for receiving
information from other neurons, and an axon specialized to conduct impulses away from the cell
body. Astrocytes function as physical, and metabolic supporters for neurons, through
detoxification, guidance during migration and regulation of energy metabolism. Moreover,
astrocytes also serve as electrical insulation for unmyelinated axons. Astrocytes are also thought
to play a vital role in regulating NSC proliferation and differentiation. Oligodendrocytes mainly
function to provide support and insulation for axons in the CNS by creating the myelin sheath.
Neurogenesis is the continuous natural growth and development of nervous tissue. Adult
neurogenesis is an active process, where adult neural progenitors differentiate and mature into
neuronal cells that integrate into the existing neural circuitry. In mammals, CNS neurogenesis
occurs in two discrete locations called neurogenic regions: the subgranular zone (SGZ) of the
dentate gyrus in the hippocampus for dentate granule cells and the subventricular zone (SVZ) of
the lateral ventricles in the forebrain for interneurons in the olfactory bulb (64) (Figure 1-9).
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Figure 1-9: Models on the Identities of Potential Quiescent NSCs in the Adult Brain. (A) Two
neurogenic regions in the adult brain: the subgranular zone (SGZ) in the dentate gyrus (DG) of the
hippocampus and the subventricular zone (SVZ) of the lateral ventricles (LV). (B) Potential
lineage relationships in the adult SVZ. (C) Potential lineage relationships in the adult SGZ (64).
The development of the mammalian cerebral cortex follows a stepwise production of
neurons, then glial cells, including astrocytes and oligodendrocytes from NSCs (65). During
embryonic development, cells of the central nervous system are derived from the neuroectoderm,
which is arranged as a neural tube which later invaginates to form structures including the
prosencephalon. Then the telencephalon is diencephalon emerge from the prosencephalon. The
cerebral cortex arises from the dorsal telencephalon and the ventral telencephalon gives rise to the
basal ganglia (65). NSCs from the dorsal and ventral telencephalon are critical to the generation
of neurons.
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Injuries, such as stroke, activate the neurogenesis mechanism outside of the described
neurogenic regions. However, whether and the extent of the active neurogenesis occurs outside the
two neurogenic regions in the mammalian CNS in vivo remain debatable. Neurogenesis is reduced
in the progression of aging, which is thought to contribute to age-related cognitive issues (66). The
mechanism of age-dependent decline in neurogenesis remains largely obscure.
1.2 Induced Neural Stem Cells (iNSCs)
The generation of neurons or glial cells to replace damaged tissue is a key step in stem cellbased therapies designed to treat neurodegenerative disease and neurological disorders (29).
Although the mechanisms that establish and maintain the multipotency of neural stem cells are
unclear, the generation of expandable NSCs is a promising therapeutic approach for treating
neurodegenerative diseases or injuries. One approach is to obtain NSCs by differentiation of
pluripotent embryonic stem cells (ESCs) as indicated on the right side of Figure 1-10. The second
approach is to reprogram the skin fibroblast cells from the patients into expandable induced NSCs
(iNSCs) as indicated in the left of Figure 1-10. The obtained expandable NSCs serve as the source
of neural cells for stem cell-based therapies designed to treat neurological disorders (Figure 1-10).
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Figure 1-10: Application of Pluripotent Stem Cells in Cell Therapy for Stroke-injured Brain. (1)
Pluripotent stem cells can be derived from blastocyst (embryonic stem cells [ESCs]) or through
reprogramming of postmitotic somatic cells, most commonly fibroblasts, generating induced
pluripotent stem cells (iPSCs). (2) Both ESCs and iPSCs can be treated in vitro to generate glia
and neurons. (3) Transplantation of glial and neuronal cells at the early stages of their development
into stroke-injured brain can lead to functional recovery through the promotion of myelinogenesis
and restoration of astrocyte network (glia) or by increasing cellular plasticity and restoring
neuronal network (neurons). OPC an indicates oligodendrocyte progenitor cell (67).
1.2.1 Generation of iNSCs using Defined Transcription Factors
Certain Transcription factors (TFs) are lineage-determining factors, which activate
necessary genes that determine a cell’s fate such as Sox2, Oct4, Klf4, and c-Myc factors.
Yamanaka et. al., reprogrammed somatic fibroblast cells into ESC-like pluripotent stem cells,
iPSCs. Induction of differentiation of the generated iPSCs to NSCs could be accomplished by
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overexpressing certain neural-lineage TFs. Despite the differentiation capabilities of pluripotent
stem cells, they were found to have ethical and practical issues (49). Specifically, the origin of
ESCs and the ability of iPSC derived cells to form tetratomic cells, respectively (49). From this
point on, many researchers have turned their focus towards reprogramming somatic cells to adult
stem cells such as NSCs, which do not form tetratomic cells.
Their et al. used the same reprogramming cocktail as Yamanaka (Oct4, Sox2, Klf4, and cMyc), but with the initial absence of Oct4 when reprogramming fibroblasts (68). In this case, cells
are thought to abandon the initial pluripotent fate and enter the NSC multipotent fate by being
overwhelmed by the overexpression of transcription factors (69). This result indicated that the TFdriving cell reprogramming technique could be used to generate adult stem cell fates such as NSCs
from somatic cells without going through the pluripotent state. Since then, scientists have spent
major effort in searching different TFs to ensure a gain of insight on the minimal combinations of
lineage-factors required to convert fibroblasts in iNSCs.
NSCs show characteristic properties that differentiate them from other types of adult stem
cells. For example, NSCs form self-renewable neuro-spheres, which can be serially passaged and
assayed using different techniques such as immunostain for assaying NSC marker proteins and
qRT-PCR for assaying NSC marker mRNAs. More importantly, NSC’s have the capability of
differentiation into tri-neural lineage cells, including neurons, astrocytes, and oligodendrocytes,
which is a key feature that can be used to characterize NSC’s.
Recently, two studies have shown that the combination of Sox2, Klf4, and c-Myc or Brn4,
Sox2, Klf4, c-Myc, and E47/Tcf3 can reprogram fibroblasts into iNSCs (70, 71). It is crucial here
to omit Oct4 form the combination because the aim is to only induce NSC’s without pluripotency.
By screening 11 lineage-determining factors, Lujan et al., and Han et al. pinpointed three to four-
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factors that induce the NSC fate. The results from both reports showed impractical long conversion
time of around 3 weeks, and very low conversion efficiencies of induced NSC’s from fibroblast
cells (as low as 0.1%) (70, 71).
Despite the low conversion efficiency, they demonstrated that when the potent c-Myc
oncogene is overexpressed, the iNSCs can self-renew and generate functional neurons in vitro and
integrate in vivo (70). In some cases, iNSCs established high self-renewal capacity with up to 130
passages in culture (70). It seemed that c-Myc overexpression is the key factor for iNSC
conversion. However, as seen in transplant studies, the overexpression of the c-Myc oncogene is
correlated with increased brain tumorigenesis (72). Moreover, Lujan et al. were also able to
generate iNSCs with the use of FoxG1 and Brn2 only (71). Further studies suggest that the
successful induction of NSCs is due to the activation of the Sox2 gene expressions by FoxG1 (70,
72).
1.2.2 Sox2 and NeuroD1 are Two Key Factors for iNSC Fate Determination
Up to now, it is still unclear which linage-determining factors are needed to efficiently
reprogram fibroblasts into high-quality iNSCs. Regardless of what approach it takes to generate
iNSCs from fibroblast cells, Sox2 seems to be a key factor. Sox2 is a master regulator factor that
is highly used for NSC identity and maintenance (73). Sox2 expression can reprogram fibroblasts
to multipotent NSCs (73).
One report used only one transcription factor (Sox2) to generate iNSCs from human and
mouse fibroblasts (29). In this study, iNSCs were shown to generate functional neurons in vitro
and can survive in vivo without the formation of tumors or tetratomic cells (29). Results of this
study also shows mouse-iNSCs (miNSCs) were passaged over 40 times, and around 20 passages
for human-iNSCs (hiNSCs) (29). This experiment also flaunted the formation of homogenous tri-
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potent populations, instead of a heterogeneous population containing different neural progenitor
cells (29).
In a cell, contrary to c-Myc overexpression, Sox2 overexpression was observed to become
silent over time. This implies that iNSCs can switch, on or off, the endogenous expression of NSC
fate-determining genes to maintain cell fate (29). Furthermore, Ring et al., also confirmed the
advantages of NSCs over PSCs by transplanting mouse brain cells induced by Sox2 and observing
the lack of tumor formation. (29).
As discussed above, many cell reprogramming techniques and/or combinations can be
performed to induce NSCs from fibroblasts, however, they all suffer from several of the following
major challenges. First, they show very low reprogramming efficiency, probably partly due to the
combination of TFs and partly due to the current gene-delivery based reprogramming technology.
Second, all studies above used invasive methods such as a virus to force the gene expression of
lineage- determining factors. “The use of a virus may have a major safety risk and possibly cause
undesired tumor formation, genotoxicity, and mutagenesis” (74). Third, the current existing cell
reprogramming procedures are less efficient, complicated, and expensive for practical use.
Neuronal Differentiation Factor 1 (NeuroD1), is a basic helix-loop-helix lineagedetermining transcriptional factor (75). NeuroD1 is required for regulating the transcription of
genes that cause neurogenesis and early differentiation of adult-born neurons (75). The
combination of TFs along with NeuroD1 can be used to reprogram mouse fibroblasts into iNSCs
with self-renewing ability (55, 68, 70, 131, 76). Moreover, one factor (Sox2) is enough to generate
self-renewable, multipotent, nontumorigenic, and lineage-restricted iNSCs (29). However, these
groups have demonstrated practical issues and very low conversion efficiencies, implying that the
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addition of neuronal fate-specifying factors to the reprogramming cocktail can influence the ability
to generate specific neuronal subtypes with much higher conversion efficiency (54, 77).
In my thesis project, I applied a patented reprogramming technology called QQ-proteininduced pluripotent stem cell (QQ-piPSC) technology, developed in Dr. Jianjun Wang’s
laboratory. This piPSC technology allows for protein-induced cell reprogramming to generate
piPSCs from somatic cells with over 90% conversion efficiency (137). I used this breakthrough
technology to reprogram fibroblast cells into protein-induced NSCs (pi-NSCs) and eliminated the
need for any invasive and unsafe methods in the traditional gene-based cell reprogramming
techniques. Second, we believed that the addition of the NeuroD1 factor along with the Sox2 factor
would lead to significantly enhanced efficiency of reprogramming fibroblasts into piNSCs with
high quality and less safety risk. Third, we demonstrated high differentiation potential of the
generated pi-NSCs into high quality and safe specialized neurons, astrocytes, and oligodendrocytes
in vitro.
1.2.3 NSC Differentiation
Here, we focus on the early steps of ESC neurogenesis, in which multiple protocols have
been established that produce pluripotent cell‐derived iNSCs. Recent studies suggest that ESC‐
derived NSCs can have the properties of embryonic radial glia, that can proliferate and generate
all types of neural derivatives, neurons, astrocytes, and oligodendrocytes (78). During early
development, the radial glia cells are the primary neural stem cells (NSCs) that generate all the
neurons as well as the glial cells and ependymal cells that persist in the CNS (79). In the embryo,
neurogenic radial glial cells are present throughout the developing CNS (79).
Two approaches have been identified to make NSCs from ESCs. One fascinating method
is to imitate the environment that produces neurectoderm in the embryo by providing appropriate
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cell-cell interactions and signals through EB formation (80). It was found that when mouse ESCs
were removed from a feeder layer and suspended without LIF growth factor that was a
maintenance factor for pluripotency, they aggregate to form an outer layer of hypoblast‐like cells
(extraembryonic visceral endoderm) surrounding an epiblast-like core collectively referred to as
an EB (primitive ectoderm) (81 & 82). The epiblast-like core in EBs can generate cell derivatives
of all three primary germ layers (endoderm, mesoderm, and ectoderm) (83). At this point, the EB
core continues to express the ESC marker Oct4 and starts to express the primitive ectoderm marker
FGF5 (81, 82, 84). The ectoderm is known to develop into the nervous system, among other types
of tissues such as hair, nails, eyes, and ears. Furthermore, the EB core may also be committed to
the ectoderm which is characterized by the expression of Sox2 (81 & 82). At this point, a
morphological transformation occurs to the columnar epithelium and it starts to look like a neural
tube, which is then followed by the expression of neurectoderm‐specific markers such as Sox1
(81 & 82). Moreover, conditions that direct the differentiation of the EB core towards
neuroectoderm will further increase the pool of cells that can differentiate into neurons and glial
cells (81 & 82).
It has been identified that signals released from the embryos anterior extraembryonic
visceral endoderm (AVE) promote the differentiation of the anterior neuroectoderm and the
visceral endoderm, EB derived ESCs behave similarly (85). However, the notochord signals
known for structuring the neural tube, are not present in the EB derived from ESCs (86). For this
reason, EBs derived from ESCs are able to generate primitive ectoderm, but not neuroectoderm or
neurons (81). This is because the signaling molecule Indian Hedgehog, which is required for the
formation of the notochord and is secreted by the visceral endoderm, promotes neurectoderm
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differentiation (80). Several other studies have shown an additional role of the hedgehog signaling
cascade in NSC proliferation in the embryo and adult mouse brain (87, 88, 89, 90).
Other studies show that the addition of retinoic acid (RA) can significantly increase the
generation of neural lineage cells. RA has a well-established dorsoventral patterning role during
development in CNS tissue (91 & 92), and ESC derivatives (93). Cells treated with RA, yield of
up to 40% neuron‐like cells, versus just a few percent observed in the cultures without RA (80).
Similar methods that utilize RA treatment, increased the yield of neural derivatives, including
glutamatergic neurons and motor neurons (92, 94, 95). However, when neural progenitors
generated by RA induction showed a limited capacity to differentiate when transplanted into the
neural tube of chick embryos, compared with ESC‐derived neural progenitors generated in the
absence of RA (96). Further drawback includes the presence of a heterogeneous mixture of cells
as the final product.
Others have also tried to include other factors, such as the use of MEDII medium which
appears to have signals that are capable of inducing neuroectoderm differentiation (80). These
NSCs do not appear to have a restricted regional identity and, when subjected to different signaling
factors, can be further induced to generate neurons or glia, as well as neural crest cells (82).
However, the molecules in the medium responsible for this activity, Hep‐G2–conditioned
medium, have not been classified and this method has not yet been applied to hESCs.
The EB selection in defined media mimics the embryo environment and this method
combines the use of an EB intermediate, in which cells of all three primary germ layers arise,
followed by a neural lineage-specific selection step (97-99). During the first several days of culture
non‐neuro-ectoderm cells, including undifferentiated ESCs, extraembryonic endoderm and
mesoderm derivatives, die, leaving a neuro-ectoderm‐derived neural progenitor population, based
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on the expression of Nestin, Sox1, Sox2, and other NSC markers (97). NSCs generated using this
approach have been used to give rise to a variety of specific neural and glial derivatives, including
oligodendrocytes (100), dopaminergic neurons, and glutamatergic neurons (101, 95). The strength
of this method is the relative purity of the final product and the ability to generate large numbers
of NSCs upon FGF2 addition (80). The weaknesses of mimicking the embryo environment in
defined media include the extended time it takes to generate NSCs (10-14 days) and, the constant
variability in the final quality of the product. The final products are usually contaminated with
mesodermal derivatives, likely due to the multiple steps (80) yeilding heterogeneous populations.
Neurogenesis of ESCs provides an in vitro culture system that can be used to characterize
the progenitor cell types involved in the differentiation, identify the active growth factors, and
signaling molecules of Neurogenesis (78). Studies show that Wnts and BMPs retrain ESC neural
differentiation, specifically by inhibiting the differentiation of primitive ectoderm and primitive
NSCs (78). Leukemia inhibiting factor (LIF) supports this inhibition, probably by supporting the
maintenance of ESC and primitive ectoderm survival (78). In contrast, Notch and FGF4 promote
the commitment of cells to the neural lineage and FGF promotes the proliferation of committed
cells like primitive NSCs (78). RA seems to have a role in ESC neural induction, however, findings
that identify its mechanism are not clear (80). Other data shows that VEGFA promotes the survival
of mature NSCs and inhibits the survival of the primitive NSCs (78). Which implies that these
growth factors and signals function in all stages of development to regulate differentiation,
proliferation, and survival of NSCs, neurons, or glial cells (78) (Figure 1-11).

28

Figure 1-11: Growth Factors and Signaling Molecules Regulate the Multistep Transition from
Embryonic Stem Cell (ESC) to Neural Stem Cell (NSC). (A) Oct4‐positive ESCs first
differentiate into primitive ectoderm‐like cells (prim ecto), which express fibroblast growth
factor‐5 (FGF5) as well as Oct4. These cells then differentiate into primitive NSCs (prim NSC),
characterized by the expression of moderate levels of nestin and Sox1, and a rounded morphology.
These cells differentiate into NSCs with an elongated‐radial glia‐like morphology that express
high levels of nestin and Sox1. LIF, Wnt, bone morphogenetic protein (BMP), Notch, FGFs,
Hedgehog (Hh), and vascular endothelial growth factor‐A (VEGFA) influence this process as
shown. (B) Images of ESC, prim ecto, prim NSC, and NSCs generated using the direct defined
medium monolayer culture approach (protocol 6) showing expression of FGF5 in prim ecto,
Sox1‐GFP (green fluorescent protein) in prim NSCs and NSCs. Note the elongated morphology
of NSCs. Another method to generate NSCs from ESCs is to the deprive ESCs of both cell–cell
interactions and signals by low density culture in serum‐free medium, triggering a mechanism for
NSC differentiation (78).
It is clear that we have just begun to understand the complex cell inducing interactions that
regulate ESC neurogenesis. The addition of specific factors, at specific stages, will allow scientists
to optimize the production of NSCs, neurons and, glial cells for transplantation therapies designed
to treat nervous system injuries of neurodegenerative diseases.
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1.3 Cell Reprogramming Methods
Many studies have been performed to improve the reprogramming methods and to apply
technology to understanding potential treatments. As mentioned before, iNSCs complement iPSC
technology which includes the molecular techniques used to reprogram to the two types of stem
cells. Many have established methods to induce the conversion of fully differentiated cells into
iPSCs or iNSCs (Figure 1-12) (3).

Figure 1-12: Four Strategies to Induce Reprogramming of Somatic Cells. (i) Nuclear transfer
involves the injection of a somatic nucleus into an enucleated oocyte which, upon transfer into a
surrogate mother, can give rise to a clone (“reproductive cloning”), or, upon explantation in
culture, can give rise to genetically matched embryonic stem (ES) cells (“somatic cell nuclear
transfer”, SCNT). (ii) Cell fusion of somatic cells with ES cells results in the generation of hybrids
that show all features of pluripotent ES cells. (iii) Explantation of somatic cells in culture selects
for immortal cell lines that may be pluripotent or multipotent. At present, spermatogonial stem
cells are the only source of pluripotent cells that can be derived from postnatal animals. (iv)
Transduction of somatic cells with defined factors can initiate reprogramming to a pluripotent state
(3).
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Up to now, four methods have been developed to reprogram somatic cells. Nuclear
transplantation (NT), the fusion of somatic cells and ESCs, culture-induced reprogramming, and
viral transduction. NT is the introduction of a nucleus from a donor somatic cell into an enucleated
oocyte to generate a cloned animal (102). The ability to generate cloned animals implicated that
the epigenetic status of differentiated cells is not permanent, and cells can be reprogrammed to an
embryonic cell that can develop into an organism (3). However, this process is inefficient (3). It
was also found that less differentiated cells are more capable of epigenetic reprogramming, greatly
reducing the efficiency when reprograming abundant somatic cells such as fibroblasts (3). Further,
the cloning of stem cells was found to be much more efficient than differentiated cells (103, 104,
105). Although NT-induced cells show no molecular or biological differences with ESCs fertilized
from fertilized embryos (105 & 106). These data implicate that NT ESCs are very useful, but the
NT method can only be used with rare unfertilized human oocytes which provides a need for more
practical methods when considering ethics (107).
The second method is the fusion of ESCs with somatic cells. This method has been shown
to reprogram somatic murine nuclei to an undifferentiated state (107-109). The resulting cells
contain many parental embryonic features, such as the activation of Oct4 markers or activation of
the somatic X chromosome, suggesting that the pluripotent phenotype is dominant (3). However,
the inefficiency of these fussed ESCs with somatic cells has shown to be inefficient and the
resulting cell is a tetraploid that limits their potential in clinical applications because of the risk of
generating large-scale genetic instability (3).
A third method to reprogram cells is called the culture-inducing reprogramming, which is
cell explantation in culture. This involves the removal of living tissue, placed in a medium for
expansion in culture which selects for immortal cell lines that may be pluripotent or multipotent
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(3). Presently, spermatogonia stem cells are the only source of pluripotency from postnatal animals
(3). Other embryonically sourced ESCs from blastomeres or the ECM and embryonic germ cells
(EGCs) can be expanded in culture and be functional in germlines (3). However, we are interested
in reprogramming somatic cells to generate adult stem cells that are present in postnatal animals.
Moreover, it is unknown whether somatic stem cell-derived cells, like those from spermatogonia
stem cells, are truly pluripotent since scientists have failed to show significant findings (3).
The fourth cell reprogramming method, viral infection of reprogramming TFs, so-called
Yamanaka iPSC technique, which suffers from several major challenges: 1) Very low
reprogramming efficiency (< 0.1%); 2) Using integrating virus to deliver pinpointed transcription
factor (TF) genes, causing major safety concerns; 3) Very complicated procedure which is
expensive for future human clinical applications (134). Moreover, viral vectors may be randomly
integrated into the host genome which increases the risk for undesired genotoxicity, mutagenesis,
and tumor formation.
1.3.1 Reprogramming by Defined Transcription Factors-Gene Delivery
In 2006, Takahashi and Yamanaka generated mouse ESC-like cells from mouse somatic
cells through viral-mediated transduction of the transcription factors Oct4, Sox2, Klf4, and cMyc
with selection for the activation of the Oct4 target gene Fbx15. These generated cells were termed
as induced pluripotent stem cells (iPSCs). They displayed morphology like that of ESCs (Figure
1-13A). Reverse transcription PCR (RT-PCR) analysis of iPSCs revealed the expression of ESC
markers Oct3/4, Nanog, Dax1, Zfp296, E-Ras, Cripto, and Fgf4 (Figure 1-13B). iPSCs were also
confirmed to be pluripotent by their ability to form teratomas (Figure 1-13D). Although unable to
generate live chimeric mice, iPSC clones were injected into blastocysts and were found to
contribute to the growth of the embryo (Figure 1-13C).
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Figure 1-13: Characterization of iPSCs Derived from Adult Mouse Tail Tip Fibroblasts. (A)
Morphology of iPS-TTFgfp4-3 on STO feeder cells. (B) RT-PCR analysis of ES marker gene
expression in iPS-TTFgfp4 cells (clones 1-5 and 7). They used primer sets that amplified
endogenous but not transgenic transcripts. (C) Contribution of iPS-TTFgfp4-7 and iPS-TTFgfp43 cells to mouse embryonic development. iPS cells were microinjected into C57/Bl6 blastocysts.
Embryos were analyzed with a fluorescence microscope at E7.5 (upper panels, iPS-TTFgfp4-7P)
or E13.5 (lower panels, iPS-TTFgfp4-3). Scale bars = 200 µm (upper panels) and 2 mm (lower
panels). (D) The E13.5 chimeric embryo was sectioned and stained with anti-GFP antibody
(brown). Cells were counterstained with eosin (blue) (5).
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On the other hand, to maintain the pluripotent state of iPSCs, they require the continuous
viral expression of SON genes. Furthermore, it was found that the endogenous Oct4 and Nanog
genes were highly methylated and expressed at lower levels or not at all when compared to ESCs.
This implicated that these iPSCs and ESCs are similar, but not identical.
The cell reprogramming method used suffers from several major challenges. Firstly, they
have found very low reprogramming efficiency (< 0.1%). Secondly, viral transduction procedures
are complicated, expensive, and have a major safety concern for future human clinical
applications. Pluripotency depends on tightly regulated levels of pluripotency genes and it has
been shown that a minimal increase or decrease of Oct4 levels causes differentiation (20). More
studies have shown that iPSCs could be successfully generated without viral integration into
specific sites (110), such as plasmid transfection (72) or non-integrating adenovirus (111),
nevertheless, these methods all suffer very low reprogramming efficiency. Thus, retroviral
integration methods are not likely to be the reason for the inefficiency.
In 2007, researchers demonstrated that selection for expression of the endogenous Nanog
and Oct4 genes, instead of the Fbx15, resulted in full reprogrammed pluripotent cells unlike
Yamanaka’s Fbx15-iPSCs just a year before (112 & 113). This implicates that even a slight
increase or decrease of Oct4 could change the cell fate. In this case, like ESCs, iPSC expression
of the endogenous Nanog and Oct4 genes were found to have hypomethylated Nanog and Oct4
promoters (112 - 114).
Human iPSCs were generated by retroviral introduction, using different sets of
transcription factors into fibroblasts (50-51). Takahashi et al. and Park et al. both showed iPSC
being generated by using Yamanaka’s reprogramming cocktail (Oct4, Sox2, Klf4, and cMyc).
Also, in 2007, Yu et al. group utilized a different cocktail (Oct4, Sox2, Nanog, and Lin28) which
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generated human iPSCs that were able to differentiate into cell types of all three germ layers in the
dish and formed mature teratomas upon injection into mice (39). The iPSC from Yu et al. more
closely resemble ESCs through morphology, patterns of DNA methylation and histone
modifications, gene expression profiles, and expression of telomerase. Other groups have also
reported the successful generation of human iPSCs from somatic cells, offering a great tool for
regenerative medicine (40, 43, 115-119).
1.3.2 Reprogramming by Defined Transcription Factors-Protein Delivery
Yamanaka’s and related methods cause many concerns. One major concern is the safety of
these iPSCs when they are used for human clinical applications. Many modified genetic methods
have been developed and have generated iPSCs with less risk (120). However, they still utilized
genetic materials and always risked unexpected genetic modifications by the exogenous sequences
in target cells (120). A few years later, in 2009, it was found that directly delivering the four
recombinant reprogramming proteins (Oct4, Sox2, Klf4, and cMyc) to reprogram somatic cells
into ESC-like iPSCs. The resulting pluripotent cells are referred to as protein-induced pluripotent
stem cells (piPSCs) (120, 121). Instead of the previous method that depends on the transcription
of delivered genes, this method avoids introducing exogenous genetic modifications to the target
cells by delivering the transcription factors themselves into the target cells.
The difficulty of accomplishing this direct delivery of proteins is passing the plasma
membrane into the cell. This challenge was solved using cell-penetrating peptide (CPP), a short
peptide sequence that contains a high amount of basic amino acids (e.g. arginine or lysine) which
are attached to the c-terminus of the reprogramming proteins (121). Researchers employed polyarginine CPPs and determined that the CPP-tagged recombinant proteins readily entered the cell
and translocated to the nucleus. They were successful in generating piPSCs.
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One group initiated their protein delivery method by first establishing stable HEK293 cell
lines that expressed each Oct4, Sox2, Klf4, and cMyc fused with a nine arginine (R) CPP and a
Myc tag to surpass the plasma membrane (122). The HEK293 extracts were then incubated with
human dermal neonatal fibroblasts (HDFn) and the intracellular translocation of proteins was
observed by immunocytochemistry by using antibodies (Figure 1-14A) (121). They found that the
efficient intracellular translocation of each reprogramming protein and translocated to the nucleus.
By testing HEK293 cell extracts they found that repeated protein treatment cycles (16 hours
protein treatment followed by 6-day incubation in ES media) yielded human p-iPSCs (Figure 114B) especially after three to four cycles yielded to iPSC-like morphology (Figure 1-14C, top
panel). However, induced cells failed to show alkaline phosphatase (AP) activity, suggesting that
the reprogramming was incomplete. However, and approximately half of these colonies were
found to be AP positive starting from the sixth cycle (Figure 1-14D).
AP-positive colonies of iPSCs were characterized as similar to hESCs and maintained for
more than 35 passages and shared common morphological characteristics and expressed markers
such as Oct4 and Nanog similar to hESCs (Figure 1-14C). Furthermore, the qRT-PCR analysis
also found similar characteristics such as the high expressions of endogenous mRNAs of ESC
markers such as Sox2, Oct4, and Nanog similar ESCs (Figure 1-15A). The protein human-induced
p-hiPSCs also formed EBs which were able to differentiate into cells of all three germ layers
(Figure 1-15D). Further testing found global gene-expression analysis to be similar to hESCs and
different from HDFn (Figure 1-15B). Moreover, after transplantation of p-hiPSCs inside the
kidney capsule of mice formed teratomas within 6-8 weeks (Figure 1-15E). p-hiPSC lines also
showed similar Bisulfite sequencing analyses to hESCs. For instance, p-hiPSCs and hESCs
showed demethylated promoter regions of Oct4 and Nanog but methylated Oct4 and Nanog in
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HDFn (Figure 1-15C). These data confirmed that p-hiPSC are pluripotent both in vitro and in
vivo.

Figure 1-14: Generation of Protein-Induced hiPSC Lines by Direct Delivery of Reprogramming
Proteins Fused with 9R as a CPP. (A) HNFs were incubated with HEK293 extracts expressing
each reprogramming protein and subjected to immunocytochemistry using myc antibodies. Nuclei
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were counterstained with DAPI. (B) The schematic protocol depicts a repeated process and the
timeline for generating phiPSCs from HNFs. (C) (Top panel) shown are starting HNFs (first
image), morphology after three-cycle protein treatments (second image), and increased colony
number after six cycles (third image). Approximately half of these iPS-like colonies stained
positive for AP; early morphology after p-hiPSC colonies were transferred to MEF is shown
(fourth image), and morphology of established p-hiPSC line is shown at passage number 10 (phiPS01 [fifth image] and p-hiPS02 [sixth image]). Immunostaining of p-hiPS01 (middle panel)
and p-hiPS02 (bottom panel) clones show expression of hESC markers, including AP, SSEA-2,
SSEA-4, Oct-4, Nanog, and Tra1-60. Nuclei were stained with DAPI (blue in the second and third
row of the panel). (D) Shown is the efficiency of reprogrammed colony formation with iPS-like
morphology and AP-positive staining after different numbers of the protein treatment cycle. This
is the summary of three independent experiments with the standard error (121).

Figure 1-15: Characterization of p-hiPSC Lines. (A) Quantitative RT-PCR was performed to
assess the expression of c-Myc, Gdf-3, Klf4, Nanog Oct4, Rex1, Sox2, and hTERT in p-hiPS01
and p-hiPS02, hES (H9), and HNF cells. Relative gene expression represents fold changes relative
to that of HNF cells normalized to β-actin expression. This experiment (repeated twice in triplicate
using independently prepared cDNAs) resulted in almost identical patterns. (B) The global geneexpression patterns were compared between p-hiPS01 and HNF, and between p-hiPS01and H9
with Affymetrix microarrays. The red lines indicate the diagonal and 5-fold changes between the
paired samples. (C) Bisulfite sequencing analysis of the Nanog and Oct4 promoters reveals almost
complete epigenetic reprogramming. Open and closed circles indicate unmethylated and
methylated CpG, respectively. Numbers on the top show each CpG location. Percentages of CpG
methylation (%Me) are shown. (D) In vitro differentiation of p-hiPSCs. Immunostaining images
(first and second-row panels) show all three germ layer cells at day 24, including neural
(ectodermal), muscle and endothelial-like (mesodermal), and endoderm-like cells (endoderm). (E)
Teratoma formation in immunodeficiency mice by p-hiPSCs. H&E staining was performed for
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teratomas. The resulting teratomas contained tissues representing all three germ layers (p-hiPS01,
first row; and p-hiPS02, second row): ectoderm, epidermal and neural tissue (rosette); mesoderm,
bone and cartilage; and endoderm, respiratory epithelium and intestinal-like epithelium (121).
P-hiPSC technology offers a new and potentially safe method for generating patientspecific stem cells (121). By eliminating the manipulation of the genome and DNA transfection,
p-hiPSCs are appropriate for potential clinical applications and research (121). However, the phiPSC colonies took double the amount of time it takes with viral transduction, about 8 weeks, and
much lower efficiency (~0.001%) when compared to virus-based methods (~0.01%) suggesting
that the published piPSC method are not efficient and require the implementation of new methods
(38, 39, 123, 134).
1.3.3 Reprogramming by Defined Transcription Factors-RNA Method
In 2010, specific synthetic modified messenger RNA (mRNA) that code for
reprogramming factors is delivered directly to cells (124). Through in vitro transcription (IVT),
mRNA was made by PCR amplicons along with the removal of 5‟ triphosphates to activate PKR
to repress protein translation, the addition of guanine cap for successful translation and increase
the half-life, and modified ribonucleotides to further the minimization of innate immune responses
to transfected RNA. They found that modified RNAs in addition to interferon inhibitor B18R
brought upon high protein expression levels and high cell viability (124). By using a cationic
vehicle to facilitate endocytosis of modified mRNAs that code for the necessary reprogramming
factors, they were able to generate RNA-iPSCs (RiPSCs) from human fibroblasts (124). However,
to sustain high levels of protein expression, the transfection of modified RNAs had to be done
daily. RiPSC colonies are then mechanically picked and expanded in ESC permissive conditions
to establish iPSC lines for characterization. Bisulfite sequencing showed demethylation patterns
like ESCs and distinct from fibroblasts. By using qRT-PCR and global gene expression profiles,
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RiPSCs displayed the expression of pluripotency genes such as SON and revealed RiPSCs having
a molecular signature like ESCs and distinct from fibroblasts.
The pluripotency-associated transcript genes including Sox2, Oct4, Nanog, Rex1, Lin28,
and DNMT3B of RiPSCs were upregulated in the RiPSCs compared to fibroblast lines. The
embryonic bodies generated for RiPSCs were able to differentiate into cell types of all three germ
layers. Lastly, the pluripotency of these cells was confirmed by their ability to form teratomas
when injected into the kidney capsules of mice. This method of inducing PSCs yielded within 17
days and higher reprogramming efficiency (~2%), versus the viral methods which usually take 4
weeks for colonies to emerge. In all, this method also eliminates the risk of genomic integration
and insertional mutagenesis. However, this method is very complex and is very difficult to be used
for human clinical applications.
1.4 Methods for Characterization of iNSCs
To prove that iNSCs have been generated, it is necessary to fully characterize them and
show the similarities to naturally occurring NSCs. It is also necessary to show their distinct
differences from the cell type they originated from. Many methods can be used to determine
whether iNSCs are multipotent, with some of these methods have been mentioned previously in
this chapter; here is a summary of the common methods.
1.4.1 Colony Formation of iNSCs
The observance of ESC-like morphology is commonly used as the initial form of
characterization for iPSCs. ESCs display round shaped colonies, large nucleoli, and scant
cytoplasm (4) and display the ability to form closely packed colonies with a clear edge, distinct
from the surrounding cells. Accordingly, NSCs form neurospheres, which are similar to ESC
colonies. The morphology of these neurospheres is distinct from the spindle-shaped fibroblast cells
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that are commonly used as the parental cells as a somatic cell source. During cell reprogramming,
the observation of typical iNSC colony morphology, the efficiency of colony formation, and
increased doubling time provide good preliminary indicators if the reprogramming protocol is
working and if there is any iNSC formation. However, the cells must meet more stringent criteria
to be considered multipotent iNSCs.
1.4.2 Immunostaining
Immunocytochemistry of the immunostaining of NSC markers is another technique that is
frequently used to characterize iNSCs. This is accomplished by using antibodies to detect the
presence of specific NSC marker proteins. The detection of common NSC marker proteins during
cell reprogramming of the starting somatic cells into iNSCs may indicate a switch or transition in
the transcriptional gene network of the somatic cells to the one that resembles NSCs.
Immunostaining of the cells is commonly performed in comparison with both the starting
fibroblast cells, as a negative control, and the reprogrammed cells during or after cell
reprogramming as an indication of the formation of iNSCs.
1.4.3 Western Blot
Western Blot is also used to detect the presence of NSC marker proteins in the newly
generated iNSCs. In a western blot, cell extracts are prepared, and the proteins contained within
are typically separated by size using SDS-PAGE gel electrophoresis before being transferred to a
membrane. The membrane is then incubated with an antibody against a specific protein for a
certain amount of time, and, washed with PBS to remove unbound antibody, then incubated with
a secondary antibody, which will bind to the primary antibody. This secondary antibody is linked
to a reporter enzyme that, when incubated with substrate, will indicate the presence of the primary
antibody and therefore, the presence of the targeted protein.
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1.4.4 qRT-PCR
Reverse transcription-polymerase chain reaction (qRT-PCR), is the most well-known
technique for absolute and relative quantification of mRNA transcription level (125). The
expression of target genes is often standardized to reference genes to eliminate sample-to-sample
partialities. Reference genes are genes that are expressed constantly in all cells to maintain
essential cellular functions (126). In this study, it is imperative to identify the appropriate reference
genes before qRT-PCR, since the accuracy of qRT-PCR is highly reliant on reference genes.
Furthermore, qRT-PCR is another technique used to detect the mRNA levels of upregulations of the common NSC marker gene expressions. In RT-PCR, mRNA extracted from cell
samples is reverse transcribed to cDNA, which is then amplified through the use of primers and a
DNA polymerase enzyme, as in traditional PCR. While immunostaining and western blotting
detect the presence of specific proteins, this method detects the presence of mRNAs the code for
specific proteins. While the qRT-PCR technique serves as an indication for the amount of
transcription of a particular gene, it does not guarantee that these transcripts will be properly
translated into a fully functional protein. Only a combination of the positive results in
immunostaining/western blot and qRT-PCR of a particular NSC marker of the reprogrammed cells
indicates the up-regulation of both gene transcription and protein translation of this NSC marker,
thus reliably indicating the success of the cell reprogramming of fibroblast cells into iNSCs.
1.4.5 DNA Demethylation Analysis
DNA demethylation analysis is the process of removing a methyl group from the
nucleotides of DNA. After an injury to nerves in mammals, DNA demethylation plays an
important role in neuro-regeneration (160). DNA methylation occurs on cytosine at CpG sites on
a gene promoter that leads to the silencing of gene expression while DNA demethylation of a gene
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promoter is associated with transcriptional activation and gene expression (156). In all, these are
called epigenetic changes.
DNA demethylation analysis of promoters of the NSC marker genes of the reprogrammed
cells is also commonly carried out via bisulfite genomic sequencing analysis to determine the
epigenetic state of these cells. In this process, bisulfite is used to determine the methylation pattern
of the DNA. Once the fibroblast cells are reprogrammed into iNSCs, the demethylation level of
the NSC marker gene is significantly decreased as compared with that of the starting cells,
indicating transcriptional activation and gene expression of this NSC marker gene.
1.4.6 In Vitro Differentiation
In vitro differentiation is utilized as a method for determining the developmental potential
of the reprogrammed iNSCs. NSCs possess the potential to differentiate into neurons and glial
cells, including astrocytes and oligodendrocytes. Therefore, the differentiation of the
reprogrammed iNSCs into astrocytes, oligodendrocytes, and neurons indicates as to whether or
not they are multipotent. In this process, the reprogrammed NSCs are cultured in the medium that
induces neural differentiation.
1.4.7 In Vivo Differentiation
When the GFP-labeled mouse iNSC (miNSC) neurospheres were microinjected into the
cortex of pups. Immunostaining revealed that miNSCs survived and differentiated into NeuNpositive neurons with mature-looking dendritic spines, Oligigo2-positive oligodendrocytes, and
GFAP-positive astrocytes 5 days after transplantation (Figure 1-16). So, miNSCs were shown to
be able to differentiate into neurons, astrocytes, and oligodendrocytes in vivo (29).
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Figure 1-16: miNSC-Derived Functional Neurons In Vitro and Multipotency of miNSCs In Vivo.
(A and B) Neurons derived from subclones miNSC-A21-B3 or miNSC-A21-B6 at 14 days in
culture express MAP2 (green) and Synapsin (red), a presynaptic marker of mature neurons. (C) A
patched neuron derived from miNSC-A21-B3 at 17 days in culture. (D and E) Whole-cell
capacitance and membrane resistance of neurons derived from miNSC-A21 were determined from
a transient 5 mV hyperpolarizing step from a holding potential of –70 mV. Values are mean ±
SEM. (F) Current-clamp recordings of neurons derived from miNSC-A21 at –40 mV reveal action
potentials with stepwise current injection. (G) Voltage-clamp recordings of neurons derived from
miNSC-A21 reveal both fast inactivating inward and outward currents indicating functional
voltage-dependent Na+ and K+ channels. (H–P) GFP-labeled miNSC-A21 were grown in
suspension cultures for 1 day to generate small neurospheres and then microinjected into the cortex
of P2–P3 wild-type pups. Five days after transplantation, mouse brains were collected, fixed,
sectioned, and immunostained. (H–J) Immunostainings reveal that miNSC-A21 can differentiate
into NeuN+ neurons (H and I) with mature-looking dendritic spines (J) in vivo. (K–M) miNSCA21 can also differentiate into GFAP+ astrocytes in vivo. (N–P) miNSC-A21 can also differentiate
into Olig2+ oligodendrocytes in vivo. Scale bars represent 2 μm in (A) and (B) and 10 μm in (C)
and (H)–(P) and include genetic analyses, epidemiology, statistics and studies in animal models.
iPSC technology expands the opportunities for research. Patient-derived iPSCs can be used to
examine the disease process at a cellular level. iPS cells can be used to test response to possible
drugs and might be used to develop patient-specific therapy (29).
Since the generation of iNSCs has been achieved by many investigators (70, 57, 29, 127),
a study of in vivo long-term survival rates, multilineage differentiation, and the functional
integration of iNSCs have been reported (128). A total of 2.25 × 105 iNSCs were transplanted into
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the cortex of adult female immunodeficient mice (8 weeks; ∼25 g; n = 9; Figure 1-17). iNSCs
were labeled using retroviral transduction along with a GFP-coding vector to distinguish
transplanted cells from the surrounding tissue. Cells were passaged at least two times and three
washing steps to make sure no remaining virus particles are present in the iNSCs, which may
induce endogenous cells after transplantation.
Six months after transplantation, an overview analysis revealed a significant long-term
survival rate in the cortex and hilus and, a densely packed graft core was detected at the injection
site and a less densely organized fraction of migrating cells that integrated within the existing
network. However, immunostain analysis has revealed that transplanted cells do not express the
NSC marker, Nestin, the cell-cycle marker, KI67, or the neural progenitor marker, DCX (Figure
1-17) (128). This implies that iNSCs have lost their stem cell identity after grafting and therefore
can be used for safe cell transplantation (128).
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Figure 1-17: iNSC-Derived Cells Show In Vivo Long-Term Survival Rates and a Multilineage
Differentiation Potential. (A) Schematic overview (left) of the two transplantation target sites in
the adult mouse brain: (1) the cortex and (2) the hilus of the dentate gyrus. Six months after
transplantation, an immunohistological analysis (right) revealed a sound survival rate of the GFPlabeled iNSCs in both regions. Image 1 displays a maximum intensity projection (MIP). Red
dashed lines indicate the hippocampus. (B) iNSC-derived cells do not express the cell-cycle
marker KI67 (upper panel) or the neural progenitor marker DCX (lower panel). The images
represent the MIPs of a confocal z stack. (C and D) iNSCs at graft edges or those that had
substantially migrated outside of the graft differentiate into TUJ1- (C) and NEUN-positive (D)
neurons and showed an orientation and shape comparable with the neighboring endogenous
neurons when transplanted into the cortex. (E and F) Transplanted iNSCs of the hilus migrate and
integrate into the granule layer of the dentate gyrus and express the neuronal marker TUJ1 (E) and
NEUN (F). Dashed lines indicate the regions of magnification. (G) iNSC-derived NEUN-positive
cells transplanted into the hilus integrated into the existing network and extended the CA3 region
of the hippocampus. Dashed lines indicate the region of magnification. (H) In both regions, iNSCs
differentiated into the glial lineage indicated via the astrocyte marker GFAP (upper panel; MIP of
a confocal z stack) and the oligodendrocyte marker OLIG2 (lower panel; the left image represents
a MIP of a confocal z stack). Nuclei were counterstained with Hoechst (128).

46
The authors also analyzed the differentiation potential of iNSCs 6 months after
transplantation by immunofluorescence staining using neuron-specific class III-beta-tubulin
(Tuj1), for immature neurons, and NeuN, which is only expressed in mature neurons (Figures 117) (128). Moreover, these induced cells integrated into the neuronal network and astonishingly
displayed identical orientations and shapes to the surrounding endogenous neurons (128). iNSCs
that experienced neuronal differentiation migrated and integrated into the granule cell layer of the
dentate gyrus (Figure 1-17). This process has been found to be like differentiation of the
endogenous neural stem cells of the SGZ (subgranular zone) (129).
1.5 Future Clinical Applications of iNSCs
The ability to reprogram somatic cells into self-renewable iNSCs has major implications
for future clinical application to treat neurodegenerative diseases. iNSCs can also serve as a model
system for revealing disease pathogenesis, drug screening, toxicity tests, cell transplantation
therapies (Figure 1-18).
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Figure 1-18: Overview of Different Approaches to Disease Modeling. Generation and
Applications of patient-specific disease models. Primary cells of patients can be used for disease
modeling, but they are not easily available and cannot be expanded in culture. Adult stem cells or
induced pluripotent stem cells (iPSCs) can be expanded in culture and differentiated into the
disease-affected cells that can be used to recapitulate disease pathogenesis in vitro. Patient-specific
disease models can be used to identify new biomarkers for improved diagnostic procedures, such
as earlier detection of disease onset. For example, hyperphosphorylated mitogen-activated protein
kinases (MAPKs) and microtubule-associated protein tau (MAPT) have recently been associated
with early susceptibility to neurodegeneration using patient-specific models of Parkinson's disease
with mutant leucine-rich repeat kinase 2 (LRRK2)29. These disease models can also be used to
identify compounds that alleviate disease pathology in vitro, which can be further developed into
novel drugs. Such compounds can be identified by targeting a novel pathway that is dysregulated
in the disease model or, alternatively, by carrying out a phenotypic screen using the disease model
to identify compounds that may act through novel mechanisms. Stem-cell-derived cells can also
form the basis for cell replacement therapies (130).
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1.5.1 Cell Replacement for Regenerative Medicine
NSCs, which exist in various regions of the CNS throughout the mammalian lifespan, can
be expanded and induced to differentiate into neurons and glia in vitro and in vivo. Because of
these characteristics, there have been increasing interests in the identification and characterization
of NSCs and neural progenitor cells both for basic developmental biology studies and for
therapeutic applications to the nervous systems. Transplantation of NSCs or their derivatives into
a host brain and the proliferation and differentiation of endogenous stem cells by pharmacological
manipulations are potential treatments for many neurodegenerative diseases and brain injuries,
such as Parkinson's disease, brain ischemia, and spinal cord injury. Continued progress in NSC
research is providing a new future for brain repair.
1.5.2 NSC Drug Discovery and Toxicology Research
Neurological diseases such as Alzheimer’s disease and Parkinson’s disease are emerging
major problems for human health, as average life expectancy is increasing globally. Drug
discovery for neurological disease remains a major challenge. Poor understanding of disease
pathophysiology and incomplete representation of human disease in animal models hinder
therapeutic drug development. Advances with iNSCs can enable modeling of human diseases on
a personal basis with the patient derived NSCs and neural cells. Utilizing iNSC-derived neurons
also advances drug compound screening and evaluation of drug efficacy. These cells have the
genetic backgrounds of patients that more precisely model disease-specific pathophysiology and
phenotypes. Therefore, applications of human iNSCs or iNSC-derived neurons are a new direction
for drug discovery in neurodegenerative diseases.
Drug testing identifies potential therapeutic compounds and increases understanding of
drug absorption, distribution, metabolism, and excretion (ADME) properties. The development of
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ADME NSC models is thought, throughout the medical community, to have a strong impact on
drug discovery and development. Human NSCs could be used for testing different drugs and toxic
environmental agents in developmental neurotoxicity studies (131). Mature neurons provide useful
drug safety screens for neurotoxicity and synaptic dysfunction (131). In the presence of reliably
expandable and physiologically relevant models, drug discovery processes become less costly.
Benefits also include more relevant research for the clinic.
Patient-specific neural cells could change the world of drug development for
neurodegenerative disease treatment. An estimated 40% of drug candidates are abandoned
throughout the development pipeline due to unforeseen adverse reactions in humans (132) and
adverse drug reactions are still the fourth leading cause of death in the United States, indicating
that current testing practices do not sufficiently predict clinical toxicity (131). Since the human
nervous system displays unique complexity and patterns of gene expression, the potential use of
these patient-derived neural cells could increase the predictability of clinical trials from preclinical
studies because current animal models used for toxicity are not always predictive of human
response. Also, these patient-derived NSCs and neurons precisely record the patients’ genetic
background which is critical for drug developments in neurodegenerative disease treatment since
patients’ genetic background may show the pathology of the patients at the molecular level. In
2002, the research community found that human neurons react differently to toxin, as compared
with mouse brains in a vaccine clinical trial for Alzheimer’s disease plaques. The vaccine is AN1792, showed severe cases of meningoencephalitis in humans that were not shown to occur in
rodent safety studies (133).
In all, in vitro toxicology assays from human iNSCs and their derivatives can offer
significant advantages over current animal models. The in vitro assays based on rodent and/or
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human transformed cell lines, largely due to improved relevance and greater versatility. More
relevant human NSC-based assays should translate into safer drugs, lower attrition rates, and a
better understanding of disease and toxicity mechanisms.
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2:

MOLECULAR
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RECOMBINANT

PROTIEN

PRODUCTION
2.1 Goal
The application of induced Neural Stem Cells (iNSCs) in science and medicine, in place
of iPSCs or ESCs, not only eliminates the controversy of utilizing human embryos to derive stem
cells (4) but also the potential to increase the efficiency of obtaining the desired cell. In contrast
with allogenic approaches that use a single source of cells to treat many patients, patient-specific
somatic cell-derived iNSCs avoids the risk of immunologic rejection in regenerative medicine
studies (39). Protein-based iPSC (piPSC) technology has provided safer opportunities for
biomedical research and clinical application (134). Complimenting piPSC technology with even
safer piNSCs with fewer differentiation options further increases the magnetism of this technology.
Furthermore, our protein-induced reprogramming technique eliminates DNA transfection and
genome manipulation, which results in human piNSCs that are appropriate for drug discovery,
disease modeling, and potential human clinical applications for neurodegeneration (121).
The viral method of reprogramming described in the previous chapter has been used to
reprogram somatic cells into iNSCs but faces many challenges. Firstly, this method is timeconsuming, taking 35 to 65 days to achieve cell reprogramming of human somatic cells into iNSCs
(120, 121). The Extended timeline renders the current iNSC technology useless for the treatment
of the disorders that demand rapid treatment. Secondly, the increased culture time makes the
current iNSC technology expensive for patients (120, 121). The current induced reprogramming
technology also faces major challenges, such as a very low conversion efficiency of 0.01% of
somatic cells into human piPSCs (120, 121) or hpiNSCs. Low conversion efficiencies are primarily
caused by the CPP-fusion protein delivery method employed. The CPP protein delivery method
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suffers several setbacks (135, 136). The CPP fusion method has low protein delivery efficiency
because the delivered proteins are sensitive to intracellular proteases, causing degradation before
the delivered proteins reach their target intracellular compartment to carry out their functions
(135). CPP fusion method also lacks the capability to deliver the proteins into the nuclei for cell
reprogramming (135). The resulting low efficiency of protein-induced reprogramming impedes
the study of the mechanism of reprogramming and prevents its application in the clinical setting.
The goal of this study was to develop a simple, fast, and efficient piNSC technology using
four reprogramming proteins. We reduce current reprogramming protocols to one simple
incubation step of somatic fibroblast cells directly with our four bacterially expressed transcription
factors to achieve the generation of piNSC within one week. We also sought to achieve nearly
~90% cell conversion efficiency by utilizing our QQ-protein delivery technology, a high yield
bacterial expression protocol, and an in vivo protein refolding system.
The QQ-protein delivery technology is developed in our lab that solves the problems
associated with the CPP-protein delivery method (137, 138). This technology involves an
incubation step of our proteins with the QQ-reagent which is polyethyleneimine (PEI) based (137).
The QQ-reagent noncovalently associates to the protein surface to maintain the proteins original
configuration. The QQ-reagent modified protein has targeting capability to deliver the protein to
the specific intracellular compartments based on the localization signal sequences carried by the
delivered proteins. QQ-modification of the protein also protects the delivered proteins form
degradation by intracellular proteases (137).
Our lab has a very high-efficiency bacterial expression method, which allows us to prepare
high yields of pure proteins (139). Our method uses a tightly controlled induction by IPTG and
utilizes both rich and minimal media to achieve a very high cell density for the production of
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recombinant proteins. This method obtained a much higher yield of recombinant proteins than the
bacterial expression system or the human cell expression system employed by the other groups
(120, 121). Our high-efficiency bacterial expression method can reduce the cost of reprogramming.
The bacterially expressed protein may not be folded properly. The in vitro protein refolding
protocols have been developed by many groups to properly refold the functional proteins (120).
However, these in vitro protein refolding techniques require an additional purification step that is
inefficient, making the reprogramming proteins expensive. Our QQ-protein delivery technology
gives us the capability of in-cell protein refolding, which is a technique that enables the direct
delivery of bacterially expressed proteins to the correct intracellular compartment of mammalian
cells for intracellular folding machinery to efficiently refold the proteins (134, 137 & 138). In the
case of cell reprogramming, we can directly deliver the QQ-modified recombinant reprogramming
proteins into the human dermal neonatal fibroblast (HDFn) cells, refold the proteins, and then
transport them to the cell nuclei to initiate cell reprogramming to generate piNSCs (134, 137 &
138).
As described above, Sox2 was found to reprogram fibroblasts to iNSCs (29). However,
further neural linage differentiation factors such as NeuroD1 are necessary to effectively
differentiate iNSCs to astrocytes, oligodendrocytes, and neurons. In our reprogramming protocol,
QQ-modified SON pluripotent reprogramming factors are used as a tool to quickly drive the
human somatic fibroblasts to a transient pluripotent state, followed by Sox2 to generate iNSCs.
The generated iNSCs shall rely on endogenous gene expression of the NSC factors to express NSC
markers and resemble wild-type NSCs in their morphology, self-renewal, and gene expression
profiles. Next, NeuroD1 is used to guide neural-lineage specific differentiation and the generated
piNSCs indicate multipotency with the capability of differentiating into neurons, astrocytes, and
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oligodendrocytes, as confirmed by the cell morphology and their specific biomarker protein
expressions.
In all, we apply our cell reprogramming technology to generate protein-induced neural
stem cells (pi-NSCs) from fibroblasts using defined TFs. Using Sox2, we will generate pi-NSCs
from human fibroblasts that are self-renewable, multipotent, nontumorigenic, and lineagerestricted cells. Secondly, we will optimize our cell-reprogramming procedure specific for NSC
generation to achieve greater than 90% conversion efficiency. Lastly, we will use NeuroD1 to
differentiate the generated pi-NSCs into neurons, astrocytes, and oligodendrocytes in vitro and in
vivo.
2.2 Molecular Cloning - Materials and Methods
The molecular cloning of Sox2, Oct4, Nanog, and NeuroD1 genes into an in-house highlevel bacterial expression vector of pET30a-sHT was previously done in Dr. Jianjun Wang’s lab
by a previous graduate student in a paper to induce iPSCs. I was not involved in this molecular
cloning work. Here I just go through the process of molecular cloning of all four proteins. The
selected reprogramming genes were amplified by PCR and subcloned into a high-level protein
expression vector pET30a-sHT. The correct sequence vectors were then transformed into bacterial
cells for bacterial expression. The expression of the bacterial proteins was carried out following
the traditional IPTG induction method. This is then followed by a purification process that uses a
His-tag column followed by QQ-modification.
2.2.1 Genes for Subclone, and Bacterial Expression Vector
Four genes were chosen for subclone-Oct4, Sox2, Nanog, and NeuroD. Each of the four
genes (Oct4, Sox2, Nanog, and NeuroD) were obtained from Addgene. Oct4, Sox2, Nanog were
chosen because they are the three proteins utilized by Dr. Wangs group to generate iPSCs.
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NeruroD1 was chosen because it’s a neural-linage differentiation factor with an ability to
sufficiently induce neuronal differentiation of neural progenitors (140).
Oct4 (NM_002701), is a member of the octamer-binding (Oct) family of transcription
factors. Oct4, as described in the previous chapter is a key regulator of stem cell pluripotency (17).
Although Oct4 is also a known oncogene and its abnormal expression is implicated in dysplastic
growth and the formation of several types of cancer (141), it is essential for mammalian
development (17).
Sox2 (NM_003106), is an SRY-related HMG-box (Sox) transcription factor. Sox2 is
highly expressed in the pluripotent cells of the early embryo and plays an important role in
maintaining potency of stem cells (11, 142). Sox2 is also a master regulator gene for NSC identity
and maintenance, as shown by the fact that knocking down Sox2 expression leads to immediate
cell cycle exit and terminal differentiation of NSCs (143, 73). In ESCs, Sox2 has been found to
form heterodimers with Oct4 to synergistically control the expression of ESC-specific genes (27,
28, 134). Multipotent cell lineages in early mouse development also depend on Sox2 function
(142). Mutations of Sox2 genes are involved with cancers and many other pathological human
disorders (134, 144-146).
Nanog (NM_024865) is a homeobox transcription factor and is a key master regulator of
pluripotency. In ESCs, low levels of Nanog cause the upregulation of transcription factors
associated with differentiation, implicating that Nanog may help sustain the pluripotent state by
repressing these factors (33 & 147). Sox2, Oct4, and Nanog (SON) bind to their own promoters
and to each other’s as an autoregulatory circuit (6).
NeuroD1 (NM_028456), is a basic helix loop helix transcription factor expressed in the
brain. This protein was chosen for its involvement in the differentiation of nervous system cells. it
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heterodimerizes with the products of the E2A gene and controls the transcription of a variety of
genes by identifying and binding E boxes in their promoter region. NeuroD1 could convert
Xenopus ectoderm into fully differentiated neurons and that it could prematurely differentiate
neural precursor cells in the nervous system (148). NeuroD1 is sufficient to induce neuronal
differentiation of neural progenitors in regions that normally do not show the addition of new
neurons (140).
For bacterial expression of the reprogramming genes, our lab used an engineered pET30a
expression vector by Novagen (Figure 2-1). The pET30a was mutated via PCR using specifically
designed PCR primers; the long His-tag was replaced by a short His-tag (six histidine residues)
and a Factor Xa cleavage site could be inserted, adding the capability of removal of short his-tag
from the reprogramming proteins (134, 149). Replacement of the long his-tag with a short his-tag
reduces the risk of the tag interfering with the proper folding of proteins (134, 149). When
interference in proper folding and function of the protein occurs, we turn to our option to remove
the His-tag by utilizing factor Xa cleavage sites and this vector was named pET30a_sHT (Figure
2-2) (134).
Along with a short His-Tag coding sequence, pET30a_sHT vector contains, a T7 lac
promoter, and for gene insertion, a multiple cloning site (MCS) that contains cleavage sites for
different and unique restriction enzymes (NcoI, EcoRV, BamHI, EcoRI, SacI, SalI, HindIII, NotI,
and XhoI) (134). Downstream of the T7 promoter, there is a lac operator, which allows us to induce
the expression of proteins using Isopropyl β-D-1-thiogalactopyranoside (IPTG) reagent (134). The
function of IPTG is to molecularly mimic allolactose. In our case, a lactose metabolite triggers the
transcription of the lac operon to induce protein expression.
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A

B

Figure 2-1: pET30a Expression Vector (Novagen). (A) Diagram of pET30a expression vector.
(B) Sequence map of the MCS of the pET30a expression vector (150).
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pET30a_sHT

Nco I
EcoRV bamHI EcoRI
atgcaccatcatcatcatcattcttctAAGGCCATGGCTGATATCGGATCCGAATTC
Sac I Sal I HindIII
Not I
Xho I
GAGCTCCGTCGACAAGCTTGCGGCCGCACTCGACACCACCACCACCACCACTGA
Figure 2-2: Sequence map of engineered pET30a_sHT (134).
2.2.2 Primer Design and PCR
For primer design, they began with two single-stranded RNA primers, a forward 5‟ primer,
and a reverse 3‟ primer. For amplification, the reverse 3‟ primer contained a sequence of bases
that are the reverse complement of the 3‟ end of the DNA coding sequence and the forward 5‟
primer was designed to contain a base sequence identical to the 5‟ end of the DNA coding
sequence. When conducting PCR on genes for subcloning, restriction enzyme (RE) cleavage sites
that are present in the vector, must be coded into the forward and reverse primers for digestion
later in the process to achieve the ligation reaction (134).
Forward and reverse PCR primers are designed for each of the four genes. The forward
primers contain bases that are identical to the 5‟ end of the coding DNA strand, and the reverse
primers were designed to contain a sequence of bases with reverse complementarity to the 3‟ end
of the coding DNA sequence, and are encoded with restriction enzyme cleavage sites that will be
used for digestion by the specific restriction enzyme later in the process.. They were designed in
this fashion to safeguard the proper annealing to the 3‟ end of the non-coding DNA, and coding
strand respectively. To safeguard proper binding of restriction enzyme, six extra bases ware
encoded onto the 5” or 3” end of each primer. PCR is then conducted for each gene in an Eppendorf
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Mastercycler Personal PCR Machine using the following the PCR recipe (Table 2-1) and PCR
process (Figure 2-3).
Table 2-1: The PCR Recipe for PCR Reaction.
PCR grade water (39 µl)
reverse primer (1.5 µl)
forward primer (1.5 µl)
template DNA (1.0 µl)
dNTP (1.0 µl)
DNA polymerase enzyme (1.0 µl)
10 x Buffer (5.0 µl)

PCR Program
Initialization step
Cycle
Denaturation
Annealing
Elongation

96°C for 3 min
94°C for 1.5 min
60°C for 1.0 min
68°C for 2.0 min

Figure 2-3: PCR Program. This program was followed for PCR amplification of each of the four
genes-Oct4, Sox2, Nanog, and NeuroD1. The Eppendorf Mastercycler Personal PCR Machine was
programmed to these specifications and the cycle was repeated 30 times for each amplification
reaction (134).
2.2.3 Restriction Enzyme Digestion and Purification of PCR Products
To remove any DNA fragments from the PCR products, they are purified through a
Clonetechchroma spin +TE-400 column. At this point, the products are digested by the specific
restriction enzymes encoded in their primers, and samples of pET30a_sHt vector were also
digested with an identical restriction enzyme for ligation (134, 150). The DNA was then incubated
for approximately 3 hours in a 37ºC water bath with restriction enzyme, a corresponding buffer,
BSA, and water.
After digestion, each of the digestion products was run on an agarose ethidium bromide
gel by electrophoresis to separate the digested DNA from other DNA fragments and purified using
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a Qiagen-QIAEXII Gel Extraction Kit and run on a 10% agarose ethidium bromide gel by
electrophoresis for confirmation.
2.2.4 Ligation of Genes into Expression Vector and Transformation of the Ligated DNA into
Competent Bacterial Cells
In a ligation reaction, an enzyme referred to as DNA ligase links two sticky ends of each
gene covalently (150). The ligation reactions occur overnight in an incubator at 4ºC of the purified
digested PCR gene product, the purified digested vector, 10 x ligase buffer, PCR grade water, and
DNA ligase enzyme. Electrophoresis is then run to confirm the presence of ligation products.
The ligated DNA is then transformed into E. coli cells. Our lab used the heath shock method
for transformation (150). Here, the ligated DNA is transferred ER2566 E. coli competent cells
through temperature changes for DNA to undergo transformation into E. coli cells. The cells are
incubated (37°C) in plates rich LB medium with kanamycin so that only those bacterial cells that
successfully taken up our vector with the resistance gene can survive. The next day, colonies are
selected and placed in rich LB medium with kanamycin until the optical density 600nm (OD600) is
~1. The culture is then combined with 1/4th the amount of glycerol to make glycerol stocks and
placed in -80°C for protein expression later in our study.
2.2.5 Screening for Positive Colonies and DNA Sequencing
Here members of my lab utilized the QIAprep Spin Miniprep Kit for the isolation of
plasmids from bacteria cells to determine if plasmid DNA contains each of the genes of interest.
The silica-gel-membrane technology can bind DNA, from which the DNA can be eluted with. The
resulting DNA solutions are then run on a 1% agarose ethidium bromide gel by electrophoresis
and subjected to digestion by the corresponding restriction enzymes used for ligation to confirm
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gene size. The digestions follow the same digestions listed for PCR. The plasmids are then sent
away for DNA sequencing for DNA sequence conformation.
2.3 Molecular Cloning – Results (This was previously done by Wang’s lab)
2.3.1 Primer Sequences and PCR Products
The designed forward and reverse PCR primers for each reprogramming gene based on the
gene sequences (Figure 2-5). All forward and reverse primers contain six initial 5‟ bases to serve
as spacer nucleotides to allow for binding of the restriction enzyme (150). Following the six spacer
nucleotides, a restriction enzyme cleavage site was encoded for each. The rest of the 24 bases of
the forward primer are designed to be identical to the first 24 bases of the gene sequence. The
reverse primer followed a similar design but used the reverse complement of the 3‟ end of the
coding gene sequence, for proper annealing to the coding DNA strand.
The restriction enzyme maps for the Oct4 gene indicates that there were no cleavage sites
for NcoI, BamHI, EcoRI, SacI, or SalI present in the gene sequence. We then selected the highly
efficient NcoI for the forward primer and EcoRI for the reverse primer (Table 2-2). The restriction
enzyme map of the Sox2 gene indicated that there were no cleavage sites within the gene sequence
for BamHI, EcoRI, SacI, and SalI, HindIII, NotI, and XhoI. For the forward primer, we selected
was the BamHI cleavage site and HindIII for the reverse primer (Table 2-2). The restriction
enzyme map of Nanog indicates that there were no cleavage sites within the gene sequence for
EcoRI, SacI, SalI, NotI, and XhoI. For the forward primer, we selected EcoRI, and XhoI for the
reverse primer (Table 2-2). The restriction enzyme map of the NeuroD1 gene indicated that there
were no cleavage sites within the gene sequence for EcoRI, SacI, SalI, NotI, and XhoI. For the
forward primer, we selected EcoRI, and XhoI for the reverse primer (Table 2-2).
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Table 2-2: Forward and Reverse PCR Primers for each of the Four Reprogramming Proteins.
Gene
PCR
Primer
Forward PCR Primer
Reverse PCR Primer
(Forward/Reverse)

BamHI/HindIII

Sox2

NcoI/EcoRI

Oct4

Nanog

NeuroD1

NcoI/XhoI

NcoI/XhoI

Sequence

Sequence

5’ cca att gga tcc atc gaa

5’ cgg ttt aag ctt tca cat

ggt cgt atg tac aac atg

gtg tga gag ggg cag tgt

atg gag acg gag 3’

3’

5’ cca att gcc atg gct atc

5’ cgg ttt gaa ttc tca gtt

gaa ggt cgt atg gcg gga

tga atg cat ggg aga gcc

cac ctg gct tcg gat 3’

3’

5’ cca att gaa ttc atc gaa

5’ cgg ttt ctc gag tca cac

ggt cgt atg atg gtg gat

gtc ttc agg ttg cat gtt cat

cca gct tgt ccc 3’

gga 3’

5’cca att gaa ttc atc gaa

5’ cgg ttt ctc gag tca cac

ggt cgt atg atg gtg gat 3’

gtc ttc agg ttg cat 3’

2.3.2 Digestion of PCR Products and Ligation
In order to successfully ligate the reprogramming genes into the pET30a_sHT expression
vector, each gene and a sample of the vector had to be digested with restriction enzymes (150).
Proper restriction enzyme digest results in the formation of sticky ends on each gene and vector,
giving the ability for sequences to line up for proper ligation. Each gene, and a sample of
pET30a_sHT, are digested with the corresponding restriction enzymes that were coded for in the
PCR primers.
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We then use agarose gel electrophoresis of the digested product for purification of these
digested products including both digested PCR product and digested vector. After purification, the
purified DNA will be used to run an agarose gel to visualize the purified DNA fragments for the
PCR product and vector to decide the amount of each DNA fragment used in the ligation reaction.
2.3.3 Plasmid Prep of Transformed Ligation Products and Positive Colony Screening
After identifying the ligation products on an agarose gel, they are transformed into
BL21[DE3] competent E. coli cells. The transformed cells were grown up on LB plates containing
kanamycin to select for E. coli colonies that have taken up the pET30a_sHT expression vector
with the kanamycin resistance gene. Plasmid prep was then performed on colonies that showed
growth to verify the uptake of the expression vector. This was done for each of the four
reprogramming genes, Sox2, Oct4, Nanog, NeuroD1.
2.3.4 DNA Sequencing
For each of the four genes, two of the plasmids that contained a gene of appropriate size
based on the gel electrophoresis results were sent for DNA sequencing to confirm the inserted gene
identity. Positive plasmids were identified for each of the four genes, and the bacteria containing
these positive plasmids were then used for protein expression. Glycerol stocks of each of the
positive bacterial cultures were properly labeled and stored in -80°C for use in protein expression.
2.3.5

Conclusions-Summary of Results
Forward and reverse PCR primers were designed for each of the four reprogramming

genes-Sox2, Oct4, Nanog, and NeuroD, based on the gene sequences, the efficiency of available
restriction enzymes on either of the four genes or the multiple clone sites of the pET30a-sHT. PCR
was then carried out for amplification of each gene sequence. The PCR products are then digested
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by restriction enzymes encoded in their forward and reverse primers of the PCR products and with
the vectors of pET30a_sHT.
The Sox2 PCR product was digested with BamHI and HindIII, resulting in the removal of
18 base pairs. Oct4 PCR product was digested with NcoI and EcoRI, resulting in the removal of
19 base pairs. Nanog PCR product was digested with EcoRI and XhoI, resulting in the removal of
18 base pairs. The NeuroD1 PCR product was digested with NcoI and HindIII, resulting in the
removal of 19 base pairs. Once the had pure digested PCR product samples of Sox2, Oct4, Nanog,
NeuroD1, and samples of pET30a_sHT vector which were then exposed to ligase and ligated with
their specific digested pET30a_sHT vectors with kanamycin resistance gene. When the ligation
products are obtained, they are transformed into BL21[DE3] E. coli cells and cultured in LB plates
containing kanamycin.
Cell colonies that are positive for the uptake of pET30a_sHT vectors containing the four
genes and kanamycin resistance are subject to plasmid preps. The resulting plasmids are then
digested with their specific restriction enzymes for verification of the target gene. Correctly sized
plasmids are then subjected to DNA sequencing to confirm the identity of genes, and no mutations
had occurred for protein expression and purification.
2.4 High Cell-Density Bacterial Expression - Materials and Methods
2.4.1 IPTG Induction Method
For bacterial expression, I used the high cell-density IPTG-induction (Figure 2-3) method
developed in Wang’s lab (139) to obtain the quantities needed for the reprogramming experiments.
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Figure 2-3: A Schematic Diagram of the High Cell-Density IPTG-Induction Method of Protein
Expression. Cell Culture temperature and time after IPTG-induction are obtained by optimization
of the protocol (139).
This expression method uses a rich medium to achieve high cell density. We started
bacterial expression using a rich LB medium, at 37°C. Once the cell density reaches a cell density
that is in the middle of the growing phase before saturation, we switched the cell culture by gently
spinning down cells and resuspending the cell pellet into the same volume of minimal M9 minimal
medium. We found that bacterial cells reach saturation at cell densities of OD600 of ∼8-10 in LB
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and OD600 of ∼10–15 in 2xYT by using a WPA Biowave© cell density meter. Thus, bacterial cells
are in the middle of the growing phase with a cell density of OD600 of 3–5 in LB. After switching
the medium, we cultured bacterial cells for another 1.0–1.5 h without adding IPTG to allow the
bacterial cells to get used to M9 minimal medium and to ensure that bacterial cells go back to the
growth phase, at the optimized temperature that is used for the cell culture after IPTG induction.
After this 1.0-1.5 h incubation without IPTG, the OD600 usually increases by 0.6-1.0 OD600 units.
IPTG (1mM) was then added to induce protein production. The cell culture is incubated at the
same optimized temperature for a period that is optimized for different proteins before cell harvest.
We found that the OD600 value at the end of cell culture increased by 2.0- to 2.5-fold compared
with the OD600 value at IPTG-induction. Therefore, before cell harvest, the bacterial cells can reach
to OD600 of 6-9 with a starting medium using LB and OD600 of 8-10 using 2× YT. The cells are
then harvested, and the protein purified (100). A schematic diagram of this protocol can be seen
in Figure 2-3.
2.4.2

Preparation of Starting Culture
Starting cultures for protein expression were prepared by adding 1 µl of glycerol stock for

each gene into LB media (Table 2-3). These cultures were then incubated in an incubator shaker
for ~5 hours at 37°C and 160-180 rpm.
LB rich medium was prepared using the following recipe:
Table 2-3: Recipe for 1-Liter Rich LB Medium used for the preparation of starting culture.
Vitamins
Kanamycin
Sterile
10x LB
Glycerol
Stock
Deionized
Stock (7.8
H2O (dH2O)
pH)
900 mL

100 mL

1 mL

1 mL

~25 µL
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10 x LB medium stock was made using 1000 g LB powders (Invitrogen) followed by
sterile deionized distilled water (dH2O) until 4 liters total, with an adjusted pH of 7.8. Once the
ingredients are added, the solution is heated and stirred until the components are completely
dissolved. The solution was poured into smaller bottles with loosened caps and autoclaved at 15
lb/in2 for 15 min. After the bottles cool to below 40°C, the caps are tightened, and the concentrated
LB rich medium is stored at room temperature.
2.4.3 Protein Induction
Once the cell density reaches a cell density that represents the middle of the growing phase
(OD600 3-5 for LB and 5-7 for 2xYT), we switched the cell culture by gently spinning down cells
and resuspending the pellet into the same volume of minimal M9 medium. M9 minimal medium
was made using stock 5 x M9 salts (Table 2-5) to make the final M9 medium used in the protein
expression and purification process (Table 2-4). After switching the medium from rich LB
medium to minimal M9 media, we cultured bacterial cells for another 1.0–1.5 h without adding
IPTG, at the optimized temperature to allow for the discharge of unlabeled metabolites. During
this period, the OD600 of the cell culture should increase by 0.5-1 OD600 units. IPTG (1mM) was
then added to induce protein production. Various IPTG concentrations and temperatures were
tested to find the optimal values for each. The induced cultures were then incubated in the 20ºC
shaker for ~16 hours to achieve maximum protein expression. We found that the OD600 value at
the end of cell culture increased by 2.0- to 2.5-fold compared with the OD600 value during IPTGinduction.
Table 2-4: Recipe for 1-Liter M9 Minimal Medium used for Bacterial Culture Protein Expression.
Sterile Deionized 5 x M9 Salts Vitamins Kanamycin
20%
1M
1M
H2O (dH2O)
(7.8pH)
Glucose
MgSO2
CaCl2
800 mL
200 mL
750 µL
1 mL
20 mL
2 mL
100 µL
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M9 is a minimal, low osmolarity media for E. Coli, resulting in a slower growth rate of
these cells. 5 x M9 salts were prepared by adding the following to a 2-liter flask (Figure 2-9).
Table 2-5: Recipe for 1-Liter 5 x M9 Stock Solution used to make M9 Minimal Medium.
1M Na2HPO4
1M KH2PO4
1M NH4Cl
1M NaCl
1M CaCl2
dH2O
34.0 g

15.0 g

5.0 g

2.5 g

15.0 mg

Top To
1.0 L

Once the ingredients are added, the solution is heated and stirred until the components are
completely dissolved. The solution was poured into smaller bottles with loosened caps and the
autoclave at 15 lb/in2 for 15 min. After the bottles cool to below 40°C, the caps are tightened, and
the M9 minimal medium is stored at room temperature.
2.4.4 Protein Purification Procedure
Upon completion of protein expression described above, the resulting cultures were then
spun down by centrifugation at 8,000 rpm for 10 minutes (7,438 G) and the supernatant was
discarded. The cell pellets were then resuspended in 1X His Binding Buffer with 6M urea (Figure
2-9) and subjected to multiple rounds of sonication to disrupt the cell membranes while releasing
the expressed protein into the supernatant. The sonication solutions were then centrifuged and the
supernatant, containing the expressed protein, was applied to a column for purification. After
purification, the four proteins of interest are eluted from the column and subjected to dialysis to
remove any residual salts from the purification process. The resulting protein solution was then
freeze-dried by lyophilization to obtain pure protein powder.
2.4.4.1 Preparation of Buffers
Stock Buffers for purification were prepared by the following recipes:
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Table 2-6: Recipes for Column Protein Purification Buffers.
1 x His-Binding
8x
Elution Buffer (2 L)
Buffer (4 L)
Charge
Buffer
(500 mL)
1440 g Urea
68.08 g
68.08 g Imidazole
Imidazole Binding buffer to 2 L
35.06 g 1M NaCl
400 mL 10X PBS
1x
final volume.
Top dH2O to 4L final Binding
volume
buffer to
Adjust pH to 7.4-7.6
500 mL
Pass through filter
final
paper
volume

Triton-100
Wash Buffer
(1 L)

Wash Buffer
(1 L)

900 mL Binding
Buffer
25 mM
Imidazole
150 mM NaCl
100 mL 0.2%
Triton

1 L Binding
Buffer
35 mM
Imidazole
150 mM NaCl

2.4.4.2 Preparation of His-tag Column
The His-tag purification columns were prepared by the addition of ~10 ml of clean NiNTA resin slurry (ThermoFisher Scientific R90110) to a clean 30 ml column. Once silica hisbinding beads settle and form a lightly packed base, they were charged using the following our
step-by-step column recharge protocol described in Table 2-7 for used Ni-NTA column.
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Table 2-7: Steps to Recharge Column for Protein Purification.
Step
Solution
1

200 mL 0.1 M EDTA

2

400 mL dH2O

3

200 mL 2% SDS

4

200 mL dH2O

5

100 mL 1M NaOH

6

1 L dH2O

7

1 L dH2O

8

1 L 1X Charge Buffer

9

1 L 1X Charge Buffer

10

100 mL 6 M Urea

2.4.4.3 Sonication of Bacterial Cells
To release the expressed protein from bacterial cells, the IPTG-induced bacterial cell
cultures are spun down at 8,000 rpm for 10 minutes at the end of protein expression. The
supernatant was discarded while the cell pellets were kept. For 1-liter of bacterial expression, the
resulting cell pellets were then resuspended in ~30 ml 1 X His Binding Buffer/6M urea and
subjected to three rounds of sonication to disrupt the cell membranes and release the expressed
proteins. Each round of sonication consisted of three exposures to high power sound waves
directed through an ultrasonic probe (ThermoFisher Scientific Sonic Dismembrator Model 500)
for 30 seconds at a power level of 21. The supernatant was always placed back on ice for 1 minute
between each sonication to prevent overheating that may degrade the protein. The cell pellet was
then resuspended in 10 ml 1X His Binding Buffer 6M urea and subjected to a subsequent round of
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sonication. This was repeated three times. After three sonication cycles, the cell pellets were spun
down for 10 minutes 12,000 rpm (17,211g) and the supernatant lysate was applied to the
purification column. A total of ~50 ml of lysate was added to each purification column. The
solutions were applied to flow through the column at a slow pace (~1 drop per second) to allow
the target protein to bind to the charged Ni-NTA beads. Before loading, we collected a sample of
the lysate (100ml, Lysate), which was properly labeled. After loading the lysates on to the column,
we also collected a flow-through sample (100ml, Flow-through), which was properly labeled.
Both samples were placed in a -20°C freezer for SDS-PAGE.
2.4.4.4 Column Wash
The column was then washed with 1L 0.2% Triton-100 to remove bacterial endotoxin. A
triton wash sample was collected and properly labeled (100 µL, Triton) for SDS-PAGE. The
column was then washed with 1L 1X His Binding Buffer with 6M urea and 25 mM 1M imidazole
to remove any bacterial junk proteins. These conditions were followed for each of the four
reprogramming factors except for NeuroD1. NeuroD1 required the imidazole concentration in the
wash to be lowered to 15 mM because the target protein would begin to elute at 20 mM. A sample
was collected in each of the washing steps for SDS-PAGE (100 µL, Wash). All of the samples
collected for SDS-PAGE were properly labeled and placed in a -20°C freezer for SDS-PAGE.
2.4.4.5 Elution of Purified Proteins
After washing the purification column and removing the impurities, the target protein was
eluted from the beads with 1 x His Binding Buffer/6M urea and 1M imidazole. The multiple elution
samples were collected at different elution volume and were properly labeled (50 µl, Elution X)
and placed in a -20°C freezer for SDS-PAGE. This elution was subjected to dialysis to remove any
residual salts from the purification process with at least 8 changes of dialysis water. After dialysis,
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the elution was placed on a lyophilizer to obtain the pure protein powders. The protein powders
obtained for each reprogramming gene were run on 10% SDS polyacrylamide gels to check their
purity. A Western Blot was then performed on each protein powder using antibodies specific to
each protein to confirm their identity.
2.4.5 Western Blot
Western blot using specific antibodies was performed on each of the protein powders
obtained to verify the identity of each protein.

I followed the western blot nitrocellulose

membranes protocol for provided by Bio-Rad.
The first step in the Western blotting procedure is to separate the macromolecules using
gel electrophoresis (151). Samples of each protein powder were dissolved in 50 µl 1X SDS loading
buffer and placed on a 90ºC heat block for 9 minutes. The samples were then removed from the
heat block, allowed to cool to room temperature, and each sample was incubated with 3 µl of
dithiothreitol (DTT) for 1 hour at room temperature to reduce any disulfide bonds. The samples
were then used to run 10% SDS-PAGE by gel electrophoresis.
Following separation by gel electrophoresis, the SDS-PAGE gel was transferred or blotted
onto a 0.2 µm PVDF nitrocellulose membrane (Bio-Rad 1620097). To do this, the Nitrocellulose
membrane is soaked in methanol because extremely hydrophobic which may hinder the movement
of aqueous buffer and protein binding in the membrane during membrane transfer. So, PVDF
membrane is hydrated with 100% methanol to facilitate effective transfer. Then we combine the
SDS-PAGE gel, two pieces of filter paper, and the nitrocellulose membrane between two sponge
pads and incubate in transfer buffer. The SDS-PAGE gel and membrane were stacked together
between the two pieces of filter paper (Mini Trans-Blot Filter Papers) and placed on a transfer
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block (referred to as a transfer sandwich). The transfer chamber was set to a maximum voltage of
150. Transfer took approximately 2.5 hours to be completed in a cold room.
Next, the membrane was incubated in 5% milk blotting blocker for 15 minutes to prevent
nonspecific binding of antibodies to the surface of the membrane, followed by overnight
incubation with the primary antibody at 4ºC in a cold room. The primary antibodies, an antibody
specifically against the target protein, was diluted 1:1000 in 5% milk diluted in 1 x TBST as a
blotting blocker. The next morning, the primary antibody was removed, and the membrane was
subjected to four (5 minutes) washes with PBS, followed by 2-hour incubation with the secondary
antibody at room temperature. The secondary antibodies were diluted 1:1000 in 5% milk diluted
in 1 x TBST. The membrane was once again subjected to four (5 minutes) washes with PBS to
remove any excess antibody.
Finally, the membrane was soaked with chemiluminescent substrate and enhancer in a dark
room and the light produced by the reaction between the substrate and the enzyme conjugated to
the secondary antibody was detected on film. Indications of light transferred to the film verified
the presence of the specific proteins.
2.5 High Cell-Density Bacterial Expression – Results
2.5.1 SDS Gel – Purification Samples
The samples collected during protein purification of Sox2 and NeruoD1 (Pre-IPTG, PostIPTG, Lysate (sonication solution), Flow-through, Triton-100, Wash, and Elution X) are run on
SDS-PAGE gel electrophoresis. Seven Samples of each of the two proteins are subject to
centrifugation and the supernatant is discarded and, sample cell pallets are then incubated in 100
µL 6M urea and stored in -20°C immediately after sample collections. After all, samples are
collected, they are quickly sonicated (2-5 seconds, power level 21) and combined 50 µl 1 x SDS
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loading buffer and placed on a 90ºC heat block for 10 minutes. The samples were then removed
from the heat block, allowed to cool to room temperature, and each sample was incubated with 3
µl of dithiothreitol (DTT) for 1 hour at room temperature to reduce any oligomers. The samples
were then run on 10% SDS gels by gel electrophoresis.
Figure 2-5 displays the results of the SDS-PAGE for each sample of the purified
bacterially expressed reprogramming proteins. For each gel, a molecular weight marker was run
to indicate size. In Panel A, Sox2 (34.3 kDa) is shown in the elution sample. While the predicted
molecular weight of the Sox2 protein is 34.3 kDa and ran to a point on the gel just above halfway
between the 34 kDa and 43 kDa indicator bands, consistent with this size. Panel B displays the
SDS-PAGE results for the purified bacterially expressed NeuroD1 purification samples. The
predicted molecular weight of the NeuroD1 protein is 39.9 kDa and on the gel, its elution sample
band is displayed just above the 34 kDa indicator band, consistent with this size.

Figure 2-5: SDS-PAGE of Reprogramming Protein Purification Samples. 10% SDS gel of
purification samples for Sox2 (34.3 kDa) and, purification samples for NeuroD1 (39.9 kDa). For
each gel, a molecular weight marker was run to indicate size; arrows indicate the position of each
protein band; (M) is molecular weight marker, (L) is lysate or sonication solution, (T-100) is the
triton-100 buffer, (W) is the wash buffer and (E) is a sample of the elution.
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2.5.2

SDS Gel – Protein Powder
Samples of each of the two protein powders were dissolved in 50 µl 1X SDS loading buffer

and placed on a 90ºC heat block for 10 minutes. The samples were then removed from the heat
block, allowed to cool to room temperature, and each sample was incubated with 3 µl of
dithiothreitol (DTT) for 1 hour at room temperature to reduce any oligomers. The samples were
then run on 10% SDS gels by gel electrophoresis.
Figure 2-6 displays the results of the SDS-PAGE for each of the purified bacterially
expressed reprogramming proteins. For each gel, a molecular weight marker was run to indicate
size. In the right two lanes, Sox2 (34.3 kDa) is shown. While the predicted molecular weight of
the Sox2 protein is 34.3 kDa and ran to a point on the gel just above 34kDa between the 34 kDa
and 43kDa indicator bands, consistent with this size. Left two lanes to display the SDS-PAGE
results for the purified bacterially expressed NeuroD1 (39.9 kDa) protein powder. The predicted
molecular weight of the NeuroD1 protein is 39.9 kDa and on the gel, its band is displayed just
above the 34 kDa indicator band, consistent with this size.
To confirm the identity of each protein powder, Western blot analysis was next carried out
on samples of each protein powder.
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Figure 2-6: SDS-PAGE of Reprogramming Protein Powders. For each gel, a molecular weight
marker was run to indicate size; arrows indicate the position of each protein band. (A) left 10%
SDS gel of purified bacterially expressed Sox2 (34.3 kDa), (B) right 10% SDS gel of purified
bacterially expressed NeuroD (39.9 kDa).
2.5.3 Western Blot
Western blot analysis was carried out on samples of each of the purified bacterially
expressed reprogramming proteins to confirm their identities. Figure 2-7 shows the western blot
results for each of the two proteins I purified, Sox2, and NeuroD1. Figure 2-8 shows the western
blot results of SON factors. Primary antibodies specific to each protein were used to confirm the
identity of each protein powder.
Anti-Sox2

Anti-NeuroD1

Figure 2-7: Western Blot Analysis Results for Sox2 and NeuroD1 Purified Recombinant Proteins
using Anti-Sox2 and Anti-NeuroD.
Anti-Sox2

Anti-Oct4

Anti-Nanog

Figure 2-8: Western Blot Analysis Results for the Three iPSC Reprogramming Proteins. Western
blot results for Sox2, Oct4, and NeuroD purified recombinant protein using anti-Sox2, anti-Oct4,
and anti-NeuroD antibodies, respectively (134).
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2.5.4 Protein Quantification and QQ-Modification
After the confirmation of the identities and purity of Sox2 and NeuroD1 proteins using
SDS-PAGE and Western Blotting, we had to finally perform QQ-reagent modification to the
proteins to generate QQ-Sox2 and QQ-NeuroD1, so that we could apply our patented QQ-protein
delivery technology. This was achieved by incubation of the protein: Sox2 and NeuroD1 with premade QQ-reagent respectively for overnight at room temperature with slow gently shaking to mix
well of protein and QQ-reagents. The QQ-reagent is a mixture of polyethyleneimine (PEI) and
lipid emulsion. The final concentration of QQ-reagent was 0.2mg/ml based on PEI concentration.
A 10% SDS-PAGE gel of QQ-Sox2 and QQ-NeuroD1 shows distinct Sox2 and NeuroD1
bands with even more distinct QQ-reagent bands (Figure 2-9A). With this combination, the
proteins are now referred to as QQ-Sox2 and QQ-NeuroD1.
In order to optimize our reprogramming protocol, the QQ-modified reprogramming
proteins were quantified. Before quantification, reprogramming proteins were filtered using a 0.2
µm filter for sterilization. Bovine serum albumin (BSA), a protein from bovine, or cows, was used
as a biological protein concentration standard. BSA was purchased in crystalline. The stock BSA
solution was diluted to span the 0.1-1 mg/mL range as shown in Table 2-8.
Table 2-8: Standard BSA Solution Preparation.
[BSA] µg/mL Volume (µL) of 10
mg/mL BSA Stock
5
100
10
200
15
300
20
400
25
500
30
600
35
700
40
800
45
900
50
1000

Volume (µL) of
MilliQ Water
495
490
485
480
475
470
465
460
455
445
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Both Sox2 and NeuroD proteins and the BSA solutions were used to run a 10% SDSPAGE. By comparing band intensities of the target protein to the BSA, it revealed an estimated
concentration of 0.4 mg/mL for QQ-NeuroD and 0.2 mg/mL of QQ-Sox2 (Figure 2-9 B).

Figure 2-9: SDS-PAGE of QQ-modified Reprogramming Proteins, QQ-Sox2, and QQ-NeuroD1,
with BSA Concentration Standard.
A Nanodrop spectrophotometer was used to confirm our BSA protein concentration results
of QQ-Sox2 and QQ-NeuroD1. Using Beers Law Spectrophotometry results revealed and
confirmed a protein concentration of 0.2 mg/mL of QQ-Sox2 and 0.45 mg/mL of QQ-NeuroD.
Equations for calculated concentrations are shown below tables.
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2.5.5 Conclusions-Summary of Results
Both reprogramming proteins Sox2 and NeuroD1 were bacterially expressed in E. coli
using the high cell density IPTG-induction method. The bacterial cultures were then sonicated,
and the expressed protein was subsequently purified using a His-tag column. Washing the column
allowed us to remove most of the impurities to obtain purified proteins of interest. The proteins
were then eluted from the column and subjected to dialysis to remove the salts that resulted from
the purification process. The eluted protein solutions after dialysis were then freeze-dried on a
lyophilized to obtain pure protein powders. The protein powders were then run on 10% SDSPAGE and the size and purity of each protein were confirmed. The identity of each of the protein
powders confirmed using Western blot analysis. The proteins were then QQ-reagent modified to
generate QQ-Sox2 and QQ-NeuroD1 and quantified using BSA as a concentration standard and
Nanodrop spectrophotometry. With the above procedure, we have successfully produced QQ-Sox2
and QQ-NeuroD1 proteins, ready for our cell reprogramming experiment of human fibroblast into
iNSCs.
2.6

Discussion
Our laboratory previously has successfully sub-cloned the genes of my two reprogramming

proteins: Sox2, and NeuroD1 into the pET30a_sHT expression vector, allowing me to perform
bacterial expression of the proteins using BL-21[DE3] E. coli cells. Through rounds of successful
protein bacterial expression and column purification, over 60 mg of pure protein powder was
obtained for both proteins whose identities were confirmed by Western blot analysis. After
numerous rounds of protein purification, I was able to isolate high-quality Sox2 and NeuroD1
protein powder to carry out the rest of the research.
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Throughout the duration of these experiments, I was able to acquire effective experimental
skills. I have learned how to perform protein expression and purification, SDS-PAGE
electrophoresis, and Western Blotting at an advanced level. These molecular biology skills will
certainly allow me to repeat these protocols in future experiments and, perform troubleshooting,
and optimize conditions when problems arise. Now, I’m also able to review literature at a more
skilled level than when I began in 2018. I have also learned how to effectively communicate,
collaborate, and report findings much more clearly and applicably. Most importantly, I have
intensified my skill of working independently in the lab through the organization, multitasking,
problem solving, and budgeting time. All these experiences have given me a strong self-disciplined
background to accompany my passion for this field.
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CHAPTER 3: GENERATION AND CHARACTERIZATION OF PROTIEN INDUCAED
NEURAL STEM CELLS (pi-NSCs)
3.1 Goal
The goal of this chapter was to apply a protein-induced pluripotency stem cell (piPSC)
technology developed in Dr. Wang’s laboratory (Patents) to produce safe, high quality, and
homogeneous protein-induced neural stem cells (piNSCs) from neonatal human dermal fibroblast
cells (HDFn). The current reprogramming technology uses viral-gene delivery techniques that
suffer from imperative challenges such as low efficiency, time-consuming, complicated,
expensive, and major safety concerns. These reprogramming methods often show a conversion
efficiency of 0.01% (5). The reprogramming procedure developed in Dr. Wang’s laboratory
includes a simple incubation step of somatic fibroblast cells with the bacterially expressed
transcription factors in media to achieve piPSC generation within 10-days with near 90%
conversion efficiency (134). We applied this reprogramming procedure to generate piNSCs within
1-2 weeks, followed by differentiation of the generated piNSCs into astrocytes, oligodendrocytes,
and neurons within two weeks.
Our reprogramming procedure utilizes a QQ-protein delivery technology, a high yield
bacterial expression protocol, and an in-cell protein refolding system. The QQ-protein delivery
technology delivers reprogramming proteins to cross the cell membrane and enter into the nuclei
of somatic fibroblast cells (137). Based on localization signal sequences carried by the
reprogramming proteins, this technology also allows us to deliver these proteins to the nucleus so
that these transcription factors can interact with the promoter and repressors of different genes on
the chromosome to regulate cell fate changes. Lastly, the QQ-reagent also protects the
reprogramming proteins from degradation by proteases (134).
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Furthermore, a low cost and high yield bacterial expression protocol, allowed us to produce
over 60 mg of recombinant Sox2 and NeuroD1 proteins. To ensure that our reprogramming
proteins were properly folded, we utilized an in-cell protein refolding technique developed in our
laboratory (152), allowing the intracellular protein folding machinery to efficiently refold the
proteins that are directly delivered into the correct intracellular compartment of the HDFn cells
(137). The folded proteins are then targeted to the cell nuclei to initiate cell reprogramming of
HDFn.
Chapter 2 outlines the subcloning and protein expression and purification of two
reprogramming proteins Sox2 and NeuroD1; resulting in the production of at least 60 mg pure
protein for each reprogramming proteins. This chapter will discuss the QQ-modification and
delivery of these proteins into HDFn, protein-induced cell reprogramming to generate piNSCs,
characterization of the generated, as well as differentiation of the piNSCs into neural tri-lineage
cells including astrocytes, oligodendrocytes, and neurons.
Previous studies have used various reprogram cocktails, with different combinations of the
transcription factors, in the reprogramming experiments to generate iPSCs. The cocktails included
the combinations of the traditional Yamanaka factors (Oct4, Sox2, Klf4, and cMyc), as well as
other combinations with new factors (Oct4, Sox2, Nanog and Lin28; Oct4, Sox2, and Nanog; Oct4
and Nanog; Nanog only) to induce iPSCs. A study has also found that only a single factor is enough
to reprogram HDFn into the neural linage (29). One of our goals is to examine new combinations
of transcription factors that allows us to eliminate oncoproteins and to provide safer piNSCs for
regenerative medicine.
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3.2 Characterization of piNSCs
In order to confirm that reprogrammed cells are multipotent, the generated piNSCs need
to be fully characterized. To achieve this goal, we used the visualization of morphology and colony
formation under the microscope and immunostaining techniques.
Neural stem cells give rise to all three neural lineages, have a capacity to self-renew (153).
In vitro differentiation is the induced differentiation of piNSCs in the neural differentiation
medium. Typically, this process involves the formation of neurons, and glia. The successful
differentiation of these cell types indicates that the cells have the developmental potential of
multipotent NSCs.
The visualization of morphology and colony formation under the microscope is commonly
used as the initial form of characterization during cell reprogramming of HDFn into piNSCs. NSCs
proliferate in neurosphere-like structures which can differentiate into complex astrocytes,
oligodendrocytes, and neurons (68). Astrocytes display heterogeneous fibrous morphologies and
are the most abundant glial cells in the central nervous system (CNS) and participate in synaptic,
circuit, and behavioral functions (154). Oligodendrocytes display highly complex structures with
extraordinary large myelin sheath extensions out of the cell membrane (155). Neurons display a
con-like cell body called the soma, a long thin axon, and numbers and dimensions of axonal and
dendritic branches (160). These cells, especially piNSCs, are distinct from the spindle-shaped
fibroblast cells. The observation of typical NSC, neuron, and glia cell morphology, the ability of
piNSCs cells to form colonies, and quick reprogramming time serve as good indicators that the
reprogramming protocol has been successful. However, these cells must face more rigorous
characterizations to be considered identical to wildtype CNS cells.
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Immunostaining for common NSC, neuron, and glia markers provides further confirmation
of successfully induced multipotency of piNSCs and their differentiation. Immunostaining
includes the use of fluorescently labeled antibodies to detect the presence of particular proteins
inside cells. The detection of common proteins in these desired cells indicates a switch from a
somatic transcriptional network to that of a multipotent NSC.
Quantitative reverse-transcription PCR (qRT-PCR) is a technique that is used to measure
the level of expression of a target gene (mRNA) (126). This is done by combining the reverse
transcription of mRNA with PCR amplification (126). PCR is technically another method to find
neural progenitor markers, serving as another indication that the cells have changed from somatic
cell gene expression patterns to NSC, neuron, and glial gene expression patterns. This technique
also serves as a method to compare gene expression patterns in different cell types, including
induced and wildtype. We originally plan to perform qRT-PCR to our piNSCs samples as well as
the samples of the induced differentiation of piNSCs into neurons, astrocytes, and
oligodendrocytes, however, due to the Covid-19 pandemic, we could not complete these
experiments.
Electrophysiology is to study the electrical properties of biological cells and tissues.
Neurons exhibit electrophysiological properties. Functional neurons derived from piNSCs, under
the conditions of primary neuron culture, express synapsin, suggesting synaptic formation in vitro
(29). A patch-clamp technique is a technique in electrophysiology to show electric currents of an
individual cell, tissues, or different areas of a cell’s membrane. Testing different areas of one cell
membrane is referred to as, whole-cell patch-clamp with voltage-clamps and current-clamps.
Voltage clamp recordings of mouse iNCS-derived neurons revealed hyperpolarized resting
membrane potential (~40 to -80 mV) with membrane resistance properties (29). Current clamp
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mode can elicit action potentials by depolarizing the membrane (29). Therefore, neurons derived
from piNSCs shall exhibit the functional membrane properties of wildtype neurons. Due to the
lack of technical expertise and equipment, we did not plan to perform patch-clamp experiment.
The formation of complex organs depends on precise spatial and temporal controls of gene
expression (156). Therefore, epigenetic mechanisms have been frequently attributed to playing a
central role in controlling cell fate determination (156). DNA demethylation analysis is an
epigenetic marker to confirm if this gene is activated for expression. DNA methylation
immunoprecipitation followed by microarray analysis of piNSCs can visually show the differences
between all types of cells used in this experiment. We did not plan to perform DNA demethylation
analysis of our piNSCs.
Reynolds and Weiss demonstrated the presence of NSCs in mouse brain by employing a
novel serum-free culture system termed the neurosphere assay (58). Neurosphere assay is a culture
system with floating clusters of NSCs and provides a method to investigate neural precursor cells
in vitro. This is achieved by suspending NSCs in medium with growth factors that lacks adherent
substrates. This method allows NSCs to form into clusters that contain a small percentage of NSCs
(158). Neurosphere assay focuses on three imperative characteristics of neural stem cells: selfrenewal, proliferation, and multipotency (158). This method is beneficial because it shows the
ability of iNSCs to integrate themselves into host CNS without disrupting normal function.
In vivo differentiation is a more stringent method for determining the developmental
potential of iNSC. To examine the in vivo developmental potential of iNSCs, researchers
transplanted iNSCs into the brains of neonatal myelin-deficient (md) rats (68). Two weeks after
transplantation, they could detect murine neural marker M2 and oligodendroglia proteolipid
protein (PLP) by immunostaining, which is deficient in the md rat brain. This in vivo
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study revealed that the implanted iNSCs might be differentiated into M2-positive cells with
astrocyte morphology in a variety of host brain regions including cortex and striatum. Many of the
M2-positive profiles could be double immunostained with an antibody against GFAP. While these
data need to be complemented by other glial markers and an assessment of in vivo neuronal
differentiation, they clearly demonstrated that iNSCs survive and give rise to differentiated neural
cells in vivo, which makes this method highly beneficial (68).
For this thesis, we examined the morphology of the generated piNSCs as well as the
differentiated neurons, astrocytes, and oligodendrocytes under a light microscope and performed
immunostaining to detect various markers of piNSCs and their differentiated neurons, astrocytes,
and oligodendrocytes. We also cultured piNSCs for an extended period (2-3 months) to show their
ability of long-term self-renewal and proliferation. Furthermore, we performed in vitro
differentiation assays and staining to show the development of potential neurons and glial cells.
3.3

Generation and Characterization of piNSCs - Materials and Methods

3.3.1

Preparation of Starting Cells
Human neonatal dermal fibroblasts (HDFn) were purchased from ThermoFisher. These

cells were plated onto gelatin-coated tissue culture plates in DMEM medium with 10% FBS
containing antibiotics to reduce the risk of infection. HDFn were incubated in a 37ºC (5% CO2)
incubator and the medium was changed as needed until their growth reached approximately 5070% confluence.
3.3.2

QQ-Protein Delivery Method
To deliver the reprogramming proteins into the cells, we used QQ-protein delivery

technology developed in our lab (137, 138, 152). The QQ-reagent efficiently delivers the protein
into the cell, protects the protein from degradation by intracellular proteases, and allows the protein
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to be targeted to the specific intracellular compartment based on the localization signal sequence
carried by the specific protein (137, 138, 152).
The process of QQ-modification of the proteins consisted of a simple overnight incubation
of the reprogramming proteins with the QQ-reagent, a polyethyleneimine (PEI), and lipid
emulsion. A stock solution of the QQ-reagent (molecular weight 1,300) was prepared in 50 mM
NaPi buffer at 25 mg/ml at pH 7.4. Approximately 1 mg of each of the reprogramming proteins
was dissolved in the same concentration of NaPi, resulting in protein concentrations between 0.5
mg/ml and 1 mg/ml. The exact protein concentration for each of the reprogramming proteins was
determined by electrophoresis with BSA as a concentration standard and confirmed by nanodrop
spectrophotometry following QQ modification. The protein was mixed with QQ-reagent, drop by
drop, and incubated in at 4 ºC overnight. The final concentration of QQ-reagent in the QQ-protein
was 0.1mg/ml. The following day, the QQ-modified protein solutions were centrifuged at high
speed to remove any precipitate that resulted from the modification process. The supernatant was
removed from the precipitate if there was any and directly used for cell reprogramming; no further
purification was needed. The QQ-modified reprogramming proteins were then mixed in DMEM
medium at specific concentrations to make reprogramming medium.
For protein-induced cell reprogramming, the delivered reprogramming proteins need to
enter the nuclei of cells to bind to different DNA promoters and repressors. The reprogramming
proteins bind to the repressors of somatic differentiation genes to silent their expression, as well
as bind to the promoter’s neural multipotent genes to activate their gene expression to initiate cell
reprogramming (10). Using a fluorescence microscope, we showed that QQ-modified
reprogramming protein, Sox2, reached to the nucleus of the majority cells within a few hours of
protein delivery (Figure 3-1). Reprogramming proteins were also observed in the cytosol of the
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cells since imaging was performed during the protein delivery cycle and the proteins were in the
dynamic process of reaching the nuclei via the cytosol after being delivered across the plasma
membrane.

Figure 3-1: Fluorescence Images of the Nuclear Targeting of the QQ-delivered Reprogramming
Protein Sox2. Immunostaining results for Sox2 3-5 hours after protein delivery through incubation
with HDFn. (Top) DAPI nuclear stain. (Bottom) Sox2 shown in Green.
3.3.3 piNSC Reprogramming Protocol
Our reprogramming protocol is a straightforward protocol that includes the preparation of
bacterially expressed proteins, quantification, QQ-modification, and 8-14 cycles of cell
reprogramming (Figure 3-2). Each cycle is applied in the growth medium or 5-16 hours per cycle.
The optimized protocol for HDFn cells begins with tree cycles of incubation with QQ-SON factors.
Each cycle is followed by incubation with regular medium for 24 hours with no QQ-modified
proteins within freshly replaced growth medium. The three QQ-SON cycles allow the fibroblasts
to be driven into a transient pluripotent state (4 Days for HDFn to iPSC-like state). This is then
followed neuronal differentiation cycles of QQ-Sox2 and QQ-NeuroD1. QQ-Sox2 (3 cycles, 4-8
days) is used to induce NSCs and, QQ-NeuroD1 (2-6 cycles, 3-20 days) is used to induce terminal
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neuronal differentiation of our iNSCs into astrocytes, oligodendrocytes, neurons. An optimized
protein concentration of 0.1 µg/ml was used for all proteins.
The cells are incubated in regular cell culture medium (10% FBS) so that they could grow
and become confluent in the dish throughout the QQ-SON induction. Once the cells reached 8090% confluence and have developed into a transient pluripotent state cell, the entire dish was
passaged, 50% to a new dish, and the remaining 50% was kept in the original dish. With the
application of QQ-Sox2, the cells are incubated in NSC medium, and with the application of QQNeuroD1 the cells are incubated in NSC differentiation medium. In all, Throughout the
reprogramming process, media is switched between cycles, beginning with regular media, then
NSC medium, and finally differentiation media. Continuous passaging was performed along with
the medium alterations yields differentiated astrocytes, oligodendrocytes, and neurons within 1922 days after QQ-SON induction of HDFn (Figure 3-2).

Figure 3-2: Schematic Diagram of the Reprogramming Protocol; including Three Different
Reprogramming Cycles of QQ-SON, QQ-Sox2, and QQ-NeuroD. Involving a few rounds of 5-16
hours incubation. Starting HDFn cells.
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3.3.4 Characterization of piNSCs, Neurons and Glial Cells
Numerous methods are available today to characterize piNSCs and determine if they are
fully reprogrammed into a multipotent state. These characterization techniques assess the
similarities between the generated piNSCs and naturally occurring NSCs.

The following

characterization techniques were utilized in these reprogramming experiments to determine the
success of each: visualization of morphology under the microscope, immunostain for multipotency
markers, and immunostain for in vitro differentiation.
3.3.4.1 Visualization of Morphology
The morphology of each of the reprogramming experiments was visualized by examination
under a light microscope as the initial measure for the success of the reprogram. NSCs display
proliferates in neurosphere-like structures which can differentiate into complex astrocytes,
oligodendrocytes, and neurons (153, 142). Astrocytes display heterogeneous fibrous morphologies
and are the most abundant glial cells in the central nervous system (CNS) and participate in
synaptic, circuit, and behavioral functions (154). Oligodendrocytes display highly complex
structures with extraordinary large myelin sheath extensions out of the cell membrane (155).
Neurons display a cell body called the soma, a long thin axon, and numbers and dimensions of
axonal and dendritic branches (159). These cells are distinct from the spindle-shaped fibroblast
cells that are commonly used as the parental cell in reprogramming experiments.
3.3.4.2 Immunostaining for NSC Markers
Immunostain using specific antibodies was carried out on the final piNSCs of each
reprogramming to detect the common NSC markers for an indication of successful
reprogramming. The iNSCs were examined for the nuclear markers, Sox2, Pax6 as well as the
intermediate filament, Nestin. For immunostain, the cells were passaged to 12-well culture wells
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attached to and incubated in the 37ºC CO2 incubator. The cell culture medium was then removed,
and the cells were washed twice with PBS for 5 minutes each time. For fixation, the cells were
treated with 10% formalin for ~10 minutes at room temperature. The fixed cells were then washed
3 times with 1 x PBS for 5 minutes each time. Next, the cells were treated with a penetration
buffer, consisting of 0.2% Triton-100, and 0.2% BSA for 2 hours at room temperature to allow the
entrance of the specific antibodies into the cells. The cells were then incubated overnight (~16
hours) at 4ºC with the primary antibody. Anti-Sox2 (1:300, Invitrogen), anti-Pax6 (1:300,
Invitrogen), and anti-Nestin (1:300, Invitrogen) were used. The cells were then washed 3 times
with the wash buffer and then incubated with the secondary antibody, which is fluorescently
labeled for 2 hours at room temperature. Alexa Fluro mouse anti-rabbit IgG (1:2000, Invitrogen),
Alexa Fluro goat anti-mouse IgG (1:2000, Invitrogen), and Alexa Fluro rabbit anti-mouse IgM
(1:2000, Invitrogen) were used. Following a final round of 3 washes with the wash buffer, the
cells were mounted with medium containing DAPI (1:5000, Invitrogen) to stain for the nucleus,
the slides were taken to the microscope imaging system for viewing of florescence. As negative
controls, the starting HDFn cells were also performed using the same immunostain procedure.
3.3.4.3 In Vitro Differentiation
In order to examine the developmental potential of piNSCs, the in vitro differentiation was
performed. The generated piNSCs were passaged to 12-well culture plates and incubated in NSC
medium (DMEM contain: 10% FBS, bFGF 20ng/ml, 0.1 mM non-essential amino acid, 2 mM Lglutamine) for 3 weeks in the 37ºC CO2 incubator. The Medium was changed as needed. The
generated piNSCs were also cultured in a special NSC differentiation medium (DMEM contain:
2-5% FBS, BFGF 10ng/ml, EFGF 10ng/ml, 0.1 mM non-essential amino acid, 2 mM L-glutamine)
that promotes differentiation into neurons and glial cells. Differentiation of the piNSCs into
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various cell types was observed under the microscope through changes in cell morphology and
was confirmed by immunostaining for specific cell markers: Tuj1 and ChAT for neurons, GFAP
for astrocytes and O4 for oligodendrocytes.
3.3.4.4 Culture of piNSCs - Long-Term Self-Renewal
The reprogrammed cells were dissociated as a single cell suspension using trypsin (0.05%)
and transferred onto new wells with NSC medium containing 1X DMEM (ThermoScientific,
11885084) with 0.1 mM Nonessential amino acid (ThermoScientific Gibco, 11140050), 2 mM
L-glutamine (ThermoScientific Gibco, 25030081), 2% FBS (ThermoScientific Gibco,
16000044), 20 ng/mL bFGF (ThermoScientific Gibco, PHG0360). Many neurospheres were
observed during self-renewal. The cells were passaged every 5 – 8 days when the dish was 8090% confluent and were cultured for over 10 passages for 2 months. The medium was prepared
fresh medium every other week and kept this medium in a cold room (4°C).
3.4 Generation and Characterization of piNSCs - Results
3.4.1 Morphology Change During Reprogramming
NSCs display proliferation in neurosphere-like structures that can differentiate into
complex astrocytes, oligodendrocytes, and neurons. The piNSCs generated by the use of our
reprogramming cocktail displayed NSC-like morphology (Figure 3-3). The reprogramming
cocktail includes QQ-SON, and QQ-NeuroD1, and QQ-Sox2. The neurospheres pictured in
Figure 3-3 resulted within the first week after whole dish passaging. For each reprogramming
cocktail, a large number of NSC-like cells with neurosphere morphology was observed at about
the same timeline.
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Figure 3-3: Pictures of piNSC Neurospheres Resulting from QQ-SON, and QQ-Sox2
Reprogramming Cocktail. (A) Untreated human dermal neonatal fibroblasts (HDFn) are shown as
a negative control. (B-F) Neurospheres. (B) Day 3. (C) Day 5. (D) Day 8. (E) Day 10. (F) Day 13.
3.4.2 Immunostaining for the Reprogrammed Cells
Immunostains were carried to detect the NSC markers: Sox2, Pax6, and Nestin.
Identification of these markers inside piNSCs provides an indication of the reprogramming of
unipotent fibroblast cells to multipotent piNSCs. To estimate conversion efficiency, we
intentionally prepared monolayer cells for these immunostains. As a negative control, the same
immunostains were performed using HDFn with the same multipotency markers and these starting
HDFn showed negative stains.
3.4.2.1 Immunostaining for Neural Stem Cells
Immunostaining for the nuclear multipotency markers Sox2, Pax6, and Nestin were carried
out on the piNSCs generated using QQ-SON and QQ-Sox2 only (Figure 3-4). Staining was
performed following the sixth passage after reprogramming. In Figure 3-4, blue DAPI stain was
used to label the nuclei of cells. The presence of Sox2 is indicated by green fluorescence. while
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the presence of Pax6 is indicated by red fluorescence. Sox2 and Pax6 must be visible inside of the
nucleus of the cell because they are transcription factors with the blue DAPI stain for the nuclei.
Co-staining indicated the cell was positive. Nestin is an intermediate filament involved in the radial
growth of axons, and is its stain shows through the cell and not limited to areas like Sox2 and Pax6
which are localized to the nucleus. A large percentage of positive cells were identified.

Figure 3-4: Fluorescence Images of Single Immunostains for NSC Markers Sox2, Nestin, and
Pax6. All cells were in the 6th passage after reprogramming cycles. (A) Nestin is indicated by
green. (B) Negative control of Nestin. (C) Pax6 indicated in red. (D) Negative control of Pax6. (E)
Sox2 is indicated in green. (F) Negative control of Sox2. Blue DAPI stain was used to indicate the
nuclei of cells. Negative controls are starting HDFn cells.
3.4.2.2 Cell Conversion Efficiency of iNSCs
The conversion efficiency to iNSCs from HDFn using a reprogramming protocol,
including cell reprogramming using QQ-Sox2, QQ-Oct4, and QQ-Nanog (QQ-SON) for three
cycles, followed by the guided neural differentiation using QQ-Sox2 alone, has been determined
based on immunostain data (Table 3-1). The immunostain data of markers Sox2, Pax6, Nestin,
and Tuj I, were analyzed. The numbers of positively stained cells versus the total number of cells
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were counted to determine the percentage of iNSCs. The percentages for each of the markers were
then averaged to determine a percentage for the overall efficiency of reprogramming.
Table 3-1 displays the results of the conversion efficiency analysis. As indicated in the
table, each of the four NSC markers indicated high cell conversion efficiencies about 80% using
the reprogramming protocol described above. While each of the NSC markers shows very similar
efficiencies, the average conversion efficiency is 78.8±4. While the NSC conversion efficiency
of the currently published literature is only ranged 0.1-0.5%, our conversion efficiency of the
piNSCs using this described reprogramming protocol above is extremely high.
Table 3-1: Efficiency of Reprogramming. For the generation of NSCs of the reprogramming
cocktail of QQ-SON followed by QQ-Sox2 alone. Average reprogramming efficiency determined
based on the percentage of cells that stained positive for the multipotency markers Tuj1, Sox2,
Pax6, and Nestin.
Markers QQ-SON & QQ-SOX2 to obtain NSCs
Tuj1
81±1
Sox2
78±5
Pax6
76±2
Nestin
80.3±1
Average 78.8±2.34
3.4.3 In Vitro Differentiation of NSCs
To examine the developmental potential of piNSCs, in vitro differentiation was performed.
When piNSCs were subjected to a neural differentiation medium that contained QQ-NeuroD, they
readily differentiated into various neural-linage restricted subtypes. Figure 3-5A shows the
pictures that indicate the morphology of undifferentiated piNSCs that have been generated using
a reprogramming protocol of the two separate cycle sets of QQ-SON, and QQ-Sox2 alone as
described above in Figure 3.2. Differentiation was carried out by incubation with the
differentiation medium for 14 days using the fifth passage of piNSCs. Pictures of control HNFs
and piNSCs are also included in the figure for comparison of morphology. The HDFn, as well as
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non-differentiated piNSCs, showed very different morphologies as compared to the differentiated
neural-lineage cells, which show morphologies of neural-like outgrowths.
Differentiation of piNSCs was further confirmed by visualization of morphology. When
piNSCs were incubated with special NSC differentiation medium they readily differentiated into
astrocytes, oligodendrocytes, and neurons (Figure 3-5). These results indicated that the piNSCs
generated have the developmental potential to develop into various cell types, aided in the visual
confirmation of their multipotency.

Figure 3-5: Morphology of HDFn, piNSCs and the Differentiated piNSCs. (A) Morphology of
the starting HDFn. (B) Morphology of the generated piNSCs. (C-F) Morphologies of the
differentiated neural-lineage restricted cells. (C, D) Neuronal-like morphology. (E) Astrocyte-like
morphology. (F) Oligodendrocyte-like morphology. Long neuronlike extensions are indicated by
arrows.
3.4.3.1 Immunostaining for Neurons
Immunostain for immature and mature neurons was carried out on cells that have been
induced differentiated into neural tri-lineage cells in a medium that contained QQ-NeuroD1
(Figure 3-6). Staining was performed for the cells generated following three passages after the last
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QQ-NeuroD1-induced differentiation cycle. In Figure 3-6, blue DAPI stain was used to label the
nuclei of cells. For TUJ 1 (Figure 3-6 A-D), NSE (Figure 3-6 E-F), and ChAT (Figure 3-6 I-L)
stains are distributed throughout the cells. A large percentage of positive cells were identified after
our reprogramming protocol versus HDFn controls with significant visual differences. The
expression of these immature (Tuj1) and mature neuron markers provides strong indication of
successful reprogramming.

Figure 3-6: Fluorescence Images of Single and Double Immunostain for Neuronal Markers TUJ1,
NSE, and ChAT. All cells were in the third passage after QQ-SON, QQ-Sox2, and QQ-NeuroD
reprogramming cycles. (A, B, C) Tuj1 shown in green. (D) Negative control for Tuj1 immunostain.
(E, F) NSE shown in red. (G) NSE shown in green. (H) Negative control for NSE immunostain.
(I, J, K) ChAT shown in green. (L) Negative control for ChAT. (F, J) Double immunostain of
NSE in red and ChAT in green. Negative controls of immunostains using starting HDFn. Blue
DAPI stain was used to indicate the nuclei of cells.
3.4.3.2 Immunostaining for Astrocytes and Oligodendrocytes
Immunostaining for astrocytes and oligodendrocytes was carried out on cells that have
been induced differentiated into neural tri-lineage cells in a medium that contained QQ-NeuroD1
(Figure 3-7). Like neuron immunostaining, this staining was performed following three passages
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after the last QQ-NeuroD1-induced differentiation cycle. Immunostain for the astrocyte marker
GFAP, and the oligodendrocyte marker O4 were carried out on the differentiated cells and control
cells (Figure 3-7). Blue DAPI stain was used to label the nuclei of cells. The presence of O4 is
indicated by red fluorescence (Figure 3-7 F-H), while the presence of GFAP is indicated by green
fluorescence (Figure 3-7 I-J). O4 and GFAP are visible throughout the cells in order to be
considered positive. A large percentage of positive cells were identified, which provides a strong
indication of successful differentiation of the piNSCs into astrocytes and oligodendrocytes. Phasecontrast images are displayed directly about immunostains (Figure 3-7 A-E). Negative controls
are also stained with O4 and GFAP markers to show unexpressed biomarkers in HDFn (Figure 37 K-L).

Figure 3-7: Fluorescence Images of Single Immunostain for Astrocytes (GFAP) and
Oligodendrocytes (O4). All cells were in the third passage after the QQ-NeuroD1-induced
differentiation cycles. (A-E) Phase-contrast image of the stains directly beneath. (F-H) O4 shown
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in red. (I-J) GFAP shown in green. (K-L) Negative controls of immunostains using starting HDFn.
Blue DAPI stain was used to indicate the nuclei of cells.
3.4.4 Conclusions-Summary of Results
In this chapter, we investigated the generation and characterization of multipotent NSCs
with NSC properties from human fibroblasts using three reprogramming factors (QQ-Sox2, QQOct4, QQ-Nanog). The conversion efficiency of piNSC generation from fibroblasts in this
experiment was 78% as determined from positive immunostaining results for NSC biomarkers
(Nestin, Pax6, and Sox2). Continuous whole-dish passaging of human reprogrammed cells showed
self-renewal capacity in the presence of growth factors, reprogramming factors, and suitable
medium. piNSCs were also stably expanded for over 10 generations in a feeder-free culture system
for 2 months. These piNSCs formed NSC-like neurospheres.
piNSCs Displayed tri-lineage developmental potential through in vitro differentiation
Immunostaining experiments using QQ-NeuroD1 alone. The expanded piNSCs readily
differentiated into various neural-linage restricted cell types such as neurons, astrocytes, and
oligodendrocytes. Characterization of piNSC tri-lineage differentiation capacity was investigated
using visual analysis of morphology and immunostaining for specific lineage biomarkers (Tuj1,
ChAT, NSE, O4, and GFAP). ChAT and NSE stain for neurons, GFAP for astrocytes and, O4 for
oligodendrocytes.
3.5 Discussion
The transplantation of neurogenic precursors into the CNS for protection and
neurodegeneration in humans with injury or disease has not achieved widespread testing and
implementation. NSCs serve as a tool for studying neural development and neurological disorders
(57). The ability to isolate NSCs is very difficult, and currently, no methods have been wellestablished to reproducibly, efficiently, and safely isolate large numbers of NSCs. Moreover, the
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ability to induce NSCs from abundant somatic cells eliminates the controversy of using human
embryos to derive stem cells.
Like NSCs, human iNSCs can undergo unlimited self-renewal, proliferation, and are
multipotent cells that are capable to differentiate into neurons and glia. However, unlike NSCs,
iNSCs can be derived from a patient’s own somatic cells, evading the risk of immunologic
rejection for in patient-specific therapies (39). iNSCs, therefore, display the potential to be utilized
in a broad range of applications such as cell replacement therapy for regenerative medicine,
pathology of neurodegenerative disease in a dish, and research of toxicity and drug discovery for
neurodegenerative disease, without the controversy and difficult isolation involved with using
human NSCs (29).
While work has been accomplished in developing iNSCs, the current techniques cause cell
reprogramming to be a random process, obstructing the study of reprogramming and the
applications for iNSCs. Gene delivery methods for iNSC generation are time-consuming, low
efficiency, and unsafe for clinical applications due to the high risk of genetic mutations. The
current protein-delivery techniques use the CPP-fused reprogramming proteins, which are not
metabolically stable and do not possess nuclear targeting capability (120, 121). In addition, these
reprogramming protocols require the delivery of high concentrations of protein furthering the
expenses required for reprogramming cells.
The reprogramming highlighted in this thesis reprograms somatic cells through the direct
delivery of reprogramming proteins, which evades the safety risks associated with the genedelivery methods. Our lab has developed an efficient QQ-protein delivery technology, to solve the
technological challenges faced by the current protein delivery technology. Our lab has also
developed a high-level bacterial expression and purification system of the reprogramming
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proteins. This was followed by an in vivo refolding protocol which, after QQ-delivery of the
proteins, employed mammalian cell machinery to properly refold the proteins. The QQ-protein
delivery technology allowed us to efficiently deliver reprogramming proteins across the cell
membrane and into the cytoplasm (137, 138, 152). The QQ reagent non-covalently binds to the
delivered proteins and protects them from degradation by intracellular proteases. This ensures that
the delivered proteins refold into their native form and possess the metabolic stability to carry out
reprogramming (137). QQ-delivered proteins can specifically localize in the targeted intracellular
compartments based on their sequence localization signals (137). Once the delivered
reprogramming proteins were properly refolded, they were targeted to the nucleus where they
carried out their functions as transcription factors.
Using this protocol, we have successfully generated piNSCs through incubation of HDFn
with QQ-modified SON (3 cycles, 5 hours each cycle) in 10% FBS medium and QQ-modified
Sox2 alone (4 cycles, 16-24 hours each cycle) in NSC medium. We further differentiated the
generated piNSCs to neurons, astrocytes, and oligodendrocytes under the differentiation medium
that contained QQ-NeuroD1 protein (4 cycles, 16-24 hours each cycle).
Following a whole-dish passaging method, the piNSCs formed neurospheres. These
piNSCs were stably and homogenously expanded for 2 months. Characterization of piNSCs by
immunostaining to confirm the expression of NSC makers. An In-depth analysis of
immunostaining data verified high cell conversion efficiencies about 80%.
Further characterization of piNSCs by in vitro differentiation confirmed the developmental
potential and multipotency of these piNSCs. Characterization of the multipotency of piNSCs was
done using immunostaining for neurons, astrocytes, and oligodendrocytes.
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Our method uses a tightly controlled induction by IPTG and utilizes both rich and minimal
media to achieve a very high cell density for the production of recombinant proteins. This method
obtained a much higher yield of recombinant proteins than the bacterial expression system or the
human cell expression system employed by the other groups (120, 121). Our high-efficiency
bacterial expression method can reduce the cost of reprogramming
Our reprogramming technology offers an efficient and fast method to generate human
piNSCs that are safe for potential human clinical applications. This technology directly delivers
bacterially expressed proteins for cell reprogramming, making this method simple and inexpensive
(134). The speed at which piNSCs are achieved with this protocol will allow for the affordable
generation of patient-specific piNSCs for transplantation. Previously used methods show very low
iNSC conversion efficiencies (0.001-0.01%) versus our QQ-protein delivery technology which
displayed high piNSC conversion efficiency (78%).
Furthermore, our reprogramming technology features an in vivo protein refolding
mechanism that enables direct delivery of bacterially expressed protein to the correct mammalian
intracellular compartment for intracellular refolding machinery to efficiently refold the proteins.
This in vivo refolding technology reduces cost when compared to previously used in vitro methods
because in vitro protein refolding protocols require an additional purification step that is
inefficient, making the reprogramming proteins expensive (120). QQ-modification of the protein
also protects the delivered proteins form degradation by intracellular proteases, which reduces the
frequency and quantity needed to reprogram fibroblasts to piNSCs.
In all, piNSCs from human dermal fibroblasts using QQ-SON pluripotent reprogramming
as a tool to quickly reset the time clock of the human somatic fibroblasts to a transient pluripotent
state, followed by QQ-Sox2 and QQ-NeuroD1-guided neural-lineage specific differentiation using
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our patented QQ-protein delivery technology. The generated piNSCs rely on endogenous gene
expression of the NSC factors to express NSC markers and resemble wild-type NSCs in their
morphology, self-renewal, and gene expression profiles. Furthermore, the generated piNSCs
indicate multipotency with the capability of differentiating into neurons, astrocytes, and
oligodendrocytes, as confirmed by the cell morphology and their specific biomarker protein
expressions. Thus, self-renewable and multipotent piNSCs without tumorigenic potential can be
generated from fibroblasts by our method.
3.6 Future Directions
The generation of clinically safe piNSCs presents a great opportunity to the scientific and
medical communities. Further investigation may be done to elucidate the mechanism of
reprogramming as well as the potential applications of these cells. Specifically, I would like to
apply transcriptomic technologies to study the transcriptome of the induced cells, the sum of all
the RNA transcripts, and compare to naturally occurring neurogenic cells. Other characterization
experiments such as DNA demethylation analysis, karyotyping, and qRT-PCR could further show
the presence of neurogenic markers. Furthermore, studies should be employed to examine various
reprogramming cocktails and reprogramming technologies to determine which achieve the highest
quality neurogenic cells. These experiments will clarify the molecular mechanisms of
reprogramming for a bigger picture of what is truly occurring during reprogramming.
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The generation of induced neural stem cells (iNSCs) and induced neuronal cells (iNCs)
from somatic cells provides new avenues for basic research and potential transplantation therapies
for neurological diseases. However, clinical applications must consider the tumor formation
capabilities of the implanted cells, the inability of iNCs to self-renew in culture, and
reprogramming methods that use retroviral transduction which permanently alter genetic network
of the cells. Here we report the generation of protein-induced neural stem cells (piNSCs) from
human dermal fibroblasts using QQ-SON pluripotent reprogramming as a tool to quickly reset the
time clock of the human somatic fibroblasts to a transient pluripotent state, followed by QQ-Sox2
and QQ-NeuroD1-guided neural-lineage specific differentiation using our patented QQ-protein
delivery technology. The generated piNSCs rely on endogenous gene expression of the NSC
factors to express NSC markers, and resemble wild-type NSCs in their morphology, self-renewal,
and gene expression profiles. Furthermore, the generated piNSCs indicate multipotency with the
capability of differentiating into neurons, astrocytes, and oligodendrocytes, as confirmed by the
cell morphology and their specific biomarker protein expressions. Thus, self-renewable and
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multipotent piNSCs without tumorigenic potential can be generated from fibroblasts by our
method.
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